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1. Introduction 
1.1. Idiopathic Pulmonary Fibrosis  
1.1.1. Overview  
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease of unknown etiology. This 
disease is more common among the elderly and the average survival rate following 
diagnosis is only 2-3 years (Sgalla et al., 2016). Histopathological examination of IPF 
lungs typically reveals extensive alveolar scarring; i.e. replacement of normal alveoli by 
fibrous scars containing myofibroblasts. The latter cells are considered to be the main 
source of excessive extracellular matrix (ECM) protein deposition, particularly collagen 
(Todd et al., 2012), not only in IPF lungs but also in fibrosis of other organs. Due to its 
progressive nature and since the process of scar formation is part of natural wound 
healing, IPF is widely regarded as an aberrant wound healing response to repetitive 
epithelial injury (Günther et al., 2012).  
 
1.1.2. Clinical manifestation and diagnosis  
Due to excessive amount of ECM during progression of IPF, patients manifest reduced 
Forced Vital Capacity (FVC), reduced DLco (Diffusion capacity of lung for carbon 
monoxide), impaired gas exchange and dyspnea combined with dry cough (Sgalla et al., 
2016). Manifestation of sub-pleural/ basal predominance, reticular abnormality and 
honeycombing with or without traction bronchiectasis in high resolution computed 
tomography and histology are the current clinical criteria for IPF diagnosis (Sgalla et al., 
2016). 
 
1.1.3. Management of IPF 
Currently, there are only two FDA-approved medications for IPF which have been proven 
to be effective in slowing the progression of IPF: Pirfenidone, which is considered as anti-
inflammatory and anti-oxidant, exerts its antifibrotic effects by antagonizing TGFβ1 
signaling (Sgalla et al., 2018). Analysis of data from the CAPACITY and the ASCEND 
trials showed that patients who received Pirfenidone experienced much slower rate of 
FVC decline compared to the placebo group (Nathan et al., 2016). Nintedanib is a multi-
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tyrosine kinase receptor inhibitor that was shown to be effective in reducing IPF 
progression (Richeldi et al., 2014). In spite of efficacy of the aforementioned medications, 
neither of them can reverse ongoing fibrosis and at best can only retard its progression.  
Despite the initial promising results of Pirfenidone, recent re-evaluation revealed that it 
cannot prevent DLco reduction in patients with advanced IPF even though it significantly 
reduces FVC decline (Yoon et al., 2018). The published report from the ASCEND trial 
showed that Pirfenidone is safe to use with acceptable side effect and it can significantly 
reduce progression of IPF (King et al., 2014). It is worthy to note that the same trial 
showed that about 16% of patients experienced decline of FVC after 52 months of 
treatment (King et al., 2014). Moreover, about 15% of patients discontinued the trials due 
to side effects (King et al., 2014). Another retrospective data analysis reported that 
Pirfenidone efficacy may diminish after 6 months in patients with severe IPF (Tzouvelekis 
et al., 2017). Considering that the conducted clinical trials were limited to only 52 weeks, 
the possible development of drug resistance to Pirfenidone or reduction of its efficacy due 
to longer treatment period is currently unknown.  
Investigating the efficacy of Nintedanib in the clinical trials unveiled its promising effects 
in reduction of FVC decline in IPF patients. It seems to be safe and generally well 
tolerated (Richeldi et al., 2014). Despite success of Nintedanib in reducing FVC decline 
by about 50%, one should note that it only retards the progress of IPF. Thus, eventual 
worsening of the disease or development of drug resistance ultimately lead to lung 
transplantation.  
 
1.1.4. Emerging novel therapeutic targets  
As mentioned above, neither Pirfenidone nor Nintedanib can reverse lung fibrosis. 
Therefore, a huge amount of research resources has been directed towards finding novel 
therapeutic targets for IPF. Hence, finding new medications which can actually reverse 
the fibrosis is now the focus of researchers around the globe. However, couple of dark 
spots make this journey far more difficult. Due to interspecies differences between rodent 
bleomycin injury and human IPF, use of rodent models for the preclinical studies isn’t the 
best option, but only available one. Furthermore, being a rare disease makes accessibility 
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of human based research material very limited. Last but not least, due to idiopathic nature 
of this disease and lack of substantial knowledge about major cells involved in the 
progression of IPF, finding new therapeutic targets is more difficult. Table 1. lists several 
of these attempts.    
Table 1. Novel therapeutic targets for IPF 
Reagents  Molecular 
mechanism  
Reference  Results of clinical trial 
GC1008  neutralizing 
antibody against 
TGFβ1 
(Madala et al., 
2014) 
Phase 1 (Terminated)(Low 
efficacy)( NCT00125385) 
BG00011 humanized 
antibody against 
αvβ6 
(Raghu et al., 
2018a) 
Phase 2A (completed) 
(promising results), 
currently at phase 2B 
Tralokinumab 
Lebrikizumab 
SAR156597 
neutralizing 
antibody against 
Interleukin 13 and 
Interleukin 13/14 
(Parker et al., 
2018; Raghu et 
al., 2018b; 
Swigris et al., 
2018) 
Phase 2A (stopped due to 
lack of efficacy) 
 
GLPG1690 antagonist of the 
LPA1 receptor 
(Maher et al., 
2018) 
Phase 1 completed 
(NCT02738801)(Promising 
results) 
BMS-986020 antagonist of the 
LPA1 receptor 
(Palmer et al., 
2018) 
Phase 1 (completed) 
(promising results) 
Phase 2 completed 
(Promising results) 
(NCT01766817) 
cocktail of 
dasatinib and 
quercetin 
cell senescence 
inducing cocktail  
(Schafer et al., 
2017) 
NA 
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Pamrevlumab 
(FG-3019) 
monoclonal 
antibody to reduce 
Connective 
Tissue Growth 
Factor activity  
(Raghu et al., 
2016) 
Phase 2 (completed) 
(Positive results) 
(NCT01890265) 
Phase 3 (Planned) 
Omipalisib 
(GSK2126458) 
highly selective 
dual inhibitor of 
PI3K and mTOR 
(Maher et al., 
2017) 
Phase 1B (completed) 
(positive results)( 
(NCT01725139)) 
Simtuzumab humanized 
monoclonal 
antibody to LOXL2 
(Barry-Hamilton 
et al., 2010) 
Phase 2 , RAINER 
(NCT01769196) and 
ATLAS (NCT01759511) 
(Terminated) (Lack of 
efficacy) 
KD025 selective inhibitor 
of ROCK2 
(Averill et al., 
2018) 
Phase 2 (completed) 
(positive results) 
(NCT02688647) 
Nintedanib plus 
Sildenafil 
 
 (Kolb et al., 
2018) 
Phase 2 (completed) (No 
beneficial effect of 
sildenafil)( NCT02802345) 
 
1.1.5. Animal models used to study lung fibrosis  
Several animal models have been developed to study the progression of lung fibrosis: 
Administration of bleomycin, which initially introduced as a chemotherapeutic antibiotic, 
resulted in development of pulmonary fibrosis in the recipients (Tashiro et al., 2017). It’s 
believed that bleomycin causes single and double stranded breaks in the DNA which 
ultimately results in increasing level of reactive oxygen species followed by epithelial cell 
death, excessive infiltration of inflammatory cells, activation of fibroblasts and extra 
cellular matrix deposition. Despite being regarded as the best fibrosis model, it has been 
subjected to sever criticism for the inability of this model to fully recapitulate fibrosis in 
humans. Majority of these criticisms concern rapid pace of its development, initiation of 
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fibrosis following inflammation and auto resolution mechanism of this model (Tashiro et 
al., 2017). Despite the aforementioned limitations, during this project we have opted to 
use this model, simply due to being the best model available to study progression and 
pathogenesis of the lung fibrosis.  
Administration of silica to the lung results development of fibrosis. Despite mimicking 
some aspects of human lung fibrosis, long waiting period usually 4-16 week, lack of 
reproducibility and fibroblastic foci, wide heterogeneity and hyperplastic epithelium in 
addition to requirement for expensive equipment’s used to aerosolize the silica 
dramatically limits applicability of this method (Tashiro et al., 2017). Administration of 
asbestosis also leads to fibrotic lungs which are very distinct from IPF lungs. Bronchial 
wall fibrosis, presence of fewer myofibroblastic foci and development of fibrosis in the 
central areas of the lung rather than sub-plural area are among the caveats of this model 
(Tashiro et al., 2017). Overexpression of cytokines such as TGF-β, TNF-α, IL-13 leads to 
increased apoptosis rate of alveolar epithelial cells and activation of fibroblasts. Even 
though these models result a highly variable and heterogeneous fibrotic response, they 
tend to mimic human disease features much better. However, these models developed 
recently, thus aren’t as well established as bleomycin model. Hence, they are currently 
more useful to study role of a specific signaling pathway in the pathogenesis of disease 
rather than recapitulating the complexity of human fibrosis (Tashiro et al., 2017). 
Induction of fibrosis via administration of fluorescent isothiocyanate, radiation-induced 
fibrosis and intravenous instillation of human IPF fibroblasts which results humanized 
model of lung fibrosis are among the other model which have been developed recently. 
They also share their own fair share of limitations and caveats. 
  
1.1.6. Cellular origin of activated myofibroblasts  
Exploring the cellular origin of activated myofibroblasts, which are the main culprit in the 
formation of fibrotic foci and deposition of ECM (Zhang et al., 1996b), is important for 
exploring novel therapeutic options to treat IPF patients.  Several cell populations have 
been proposed to be the cell-of-origin for activated myofibroblasts in lung fibrosis. 
Resident fibroblasts are a heterogeneous population of cells located in the lung 
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interstitium. These cells are plastic and play important roles during both normal lung 
homeostasis and repair after injury (Sontake et al., 2019). Several groups have already 
shown major contribution of these resident cells to activated myofibroblasts at the event 
of lung injury (Barron et al., 2016; Hung et al., 2013; Kendall and Feghali-Bostwick, 2014). 
However, identity of these cells and the molecular mechanisms involved in the process 
are not sufficiently studied. 
Fibrocytes are mesenchymal progenitor cells originated from bone marrow which can be 
found in the fibrotic foci. However, their contribution to activated myofibroblast pool in the 
IPF via transdifferentiation is controversial (Maharaj et al., 2013). Moore et al., provided 
evidences that these cells migrate to the area with active fibrosis and can produce 
cytokines which are crucial for the progression of fibrosis (Moore et al., 2006). However, 
direct differentiation of fibrocytes to activated myofibroblasts is the topic of debates in the 
scientific community.  
Pericytes are another group of perivascular, mesenchymal like cells which contribute to 
progression of lung fibrosis. Like fibrocytes, they are subject of many scientific debates 
regarding their ability to transdifferentiate to activated myofibroblasts. Using lineage 
tracing tools Rock et al., didn’t observe transdifferentiation of NG2+ and Foxj1+ cells to 
activated myofibroblasts (Rock et al., 2011). On the other hand, a more recent study 
managed to provide evidences regarding contribution of NG2+/ Pdgfrbβ+ double positive 
pericytes to the pool of activated myofibroblast (Hung et al., 2013). Considering published 
reports, further research is required to resolve these controversies.  
Another one of controversial sources which have been described to contribute to the pool 
of activated myofibroblasts are epithelial cells. Based on evidence provided in one study, 
epithelial cells undergo Epithelial to Mesenchymal Transition (EMT) and differentiate to 
activated myofibroblasts following exposure to TGFβ1 signaling pathway (Tanjore et al., 
2009). In comparison, using lineage tracing tools, Kim et al., didn’t observed a major 
transition of epithelial cells to activated myofibroblasts (Kim et al., 2006). These 
discrepancies might be due to difference in animal models which have been used in the 
previous studies and warrant further research. 
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1.2. Lipofibroblasts in the developing lung: overview  
The lung mesenchyme consists of serval different cell types that play various roles during 
homeostasis. One of the understudied mesenchymal cell types in the lung is the lipid droplet-
containing interstitial fibroblast, also known as the lipofibroblast (LIF). LIFs were first identified in 
1970 via electron microscopy imaging of the developing lung (O’Hare and Sheridan, 1970). They 
have been described as lipid droplet-containing fibroblasts residing in close proximity to type II 
alveolar epithelial cells (AECII). However, detailed characterization of these cells during normal 
development of lung, homeostasis and disease progression is still lacking substantial details. 
Initial reports provided evidence regarding their heterogeneity and suggested potential role of 
LIFs in alveolarization and restructuring of the lung (Brody and Kaplan, 1983; Maksvytis 
et al., 1981). Furthermore, Tordet et al. reported that increasing level of diacylglycerols 
and triacylglycerols starting at E17.5 in the rats lung coincides with the appearance of 
lipofibroblasts (Tordet et al., 1981). Considering all the available information at that time, 
it was proposed that these cells support AECIIs in the process of pulmonary surfactant 
production via storing and transferring lipid molecules to these cells as was later 
demonstrated by Torday et al. (Torday et al., 1995). Torday et al, revealed that labeled 
fatty acids accumulated in the lipofibroblasts shuttle to AECIIs (Torday et al., 1995). 
Several pieces of evidence revealed that LIFs require active PPARg signaling pathway 
which leads to expression of PLIN2, also known as ADRP (Adipocyte Differentiation 
Related Protein), as well as other lipid binding proteins and finally accumulation of lipid 
droplets (McGowan et al., 1997; Schultz et al., 2002). In an attempt to study the molecular 
mechanisms involved in formation and maintenance of the lipofibroblasts, Schultz et al., 
isolated AECII and lipofibroblasts and assessed expression level of Plin2. Their data 
showed increased level of Plin2 as a downstream target of Pparg, which binds and 
encapsulated lipid droplets in lipofibroblasts that harbor active fatty acid synthesis and 
storage mechanism. On the other hand, AECIIs which dont store lipid droplets, express 
minimal levels of Plin2. In addition to PLIN2 and PPARg, THY-1 (Friedmacher et al., 
2014), parathyroid hormone-related protein (Rehan and Torday, 2014) and leptin are 
among other markers of LIFs. Overexpression of Thy-1 in Thy-1 negative cells, increases 
expression of Pparg and its co-receptor, RXR-α, and eventually Plin2 (Varisco et al., 
2012). Despite increasing level of attention toward LIFs in the past years, their origin and 
potential role in pulmonary diseases remain unclear. El Agha et al. carried out genetic 
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lineage tracing using a novel Fgf10Cre-ERT2; tomatoflox line to show that FGF10+ cells 
labeled at either E11.5 or E15.5 give rise lipofibroblasts at the end of gestation (E18.5) 
(El Agha et al., 2014). It’s worthy to note that only a fraction of lipofibroblasts derives from 
the FGF10+ lineage. Recently, it has been shown that mesenchymal cells expressing 
Tcf21 are also progenitors for LIFs during embryonic lung development (Park et al., 
2019). It remains to be established how distinct the FGF10+ and TCF21+ cell populations 
are, and whether there are other unknown cellular sources for LIFs in the developing lung. 
 
1.2.1. PPARg signaling pathway  
The signature signaling pathway that is believed to be required for the formation and 
maintenance of lipofibroblasts is the PPARg signaling cascade (El Agha et al., 2017; 
McGowan et al., 1997). PPARg is part of a bigger family of PPARs (PPARa, PPARb, 
PPARg and PPARd) that after shuttling into the nucleus exert their function via binding to 
PPAR Responsive Element (PPRE) in the promoter region of their target genes. Although 
they share similarities in their structure, each member of the PPAR family has unique 
functions as reflected by distinct tissue distribution and differential response to distinct 
ligands (Poulsen et al., 2012). The PPARg gene encodes two variants, PPARg1 and 
PPARg2 as a result of having two transcription start sites as well as alternative splicing. 
PPARg1 is expressed ubiquitously in various cell types in the body while PPARg2 is 
exclusively expressed in adipocytes (Medina-Gomez et al., 2007; Tontonoz and 
Spiegelman, 2008). 
 
1.2.2. PPARg signaling plays different roles in different pulmonary cells      
Since its discovery, due to the complexity and importance of this signaling cascade, 
PPARg signaling has been an interesting research topic. Several crucial roles have been 
described for PPARg signaling including but not limited to various roles in adipogenesis, 
differentiation and maintenance of adipocytes (Tontonoz and Spiegelman, 2008), cellular 
metabolism (Tomaru et al., 2009), cell cycle control and tumorigenesis (Penna et al., 
2016; Sjodahl et al., 2019), obesity and insulin resistance (Marginean et al., 2018), 
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modulation of immune system and immune response (Martin, 2010; Speca et al., 2014; 
Vallee et al., 2018), mitochondrial function and regeneration (Corona and Duchen, 2016) 
and others. Reddy et al., provided evidence that activation of PPARg, which in turn results 
in increasing levels of GPx3, protects murine lungs from cigarette smoke-induced Chronic 
Obstructive Pulmonary Diseases (COPD) (Reddy et al., 2018). Another study reported a 
protective role for PPARg signaling against cigarette smoke induced inflammation via 
activation of AMP-activated protein kinase (AMPK) (Wang et al., 2018). Furthermore, 
activation of this signaling cascade protects against LPS-induced acute lung injury (Jiang 
et al., 2018) as well as Pulmonary Arterial Hypertension (PAH) (Rashid et al., 2018).  
 
1.2.3. PPARg signaling in Idiopathic Pulmonary Fibrosis 
PPARg signaling is significantly altered in fibrotic disease of the lung as well as other 
organs (Burgess et al., 2005; Marra et al., 2000). Treatment of fibroblasts with TGFβ1 
results in suppression of PPARg signaling, a process that can be rescued via 
supplementation with PPARg agonists (Bartram and Speer, 2004; Burgess et al., 2005). 
Treatment of human lung fibroblasts with recombinant human TGFβ1 leads to increased 
phosphorylation of SMAD3/SMAD4, shutting of this complex into the nucleus and binding 
to consensus TGFβ1 inhibitory element (TIE) and also to canonical SMAD-binding 
elements (SBEs) at PPARg promoter. Occupation of these binding sites with 
SMAD3/SMAD4 complex results in inhibition of PPARg expression (Lakshmi et al., 2017). 
On the other hand, activation of PPARg-RXR heterodimer leads to suppression of TGFβ1 
expression via dephosphorylation of zinc-finger transcription factor-9. Furthermore, 
PPARg induces expression of PTEN (phosphatase and tensin homologue deleted on 
chromosome 10)  which in turn can suppress TGFβ1 expression in a p70 ribosomal S6 
kinase-1 dependent manner (Lee et al., 2006). Moreover, PPARg is the key link 
between BMP2 and TGFβ1 signaling which seems to play a major role in the progression 
of PAH (Calvier et al., 2017). Due to significance of TGFβ1 and BMP2 signaling pathway 
in IPF pathogenesis, this link is potentially critical in the pathogenesis of IPF as well. 
Furthermore, PPARg can bind to the PPRE element in the promoter region of PETN which 
can attenuate differentiation of activated myofibroblasts (Teresi et al., 2006; White et al., 
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2006). 15-deoxy-(12,14)-15d-prostaglandin J2, another natural PPARg agonist, can 
attenuate TGFβ1 induced phosphorylation of AKT at serine 473 which in return blocks 
differentiation of fibroblasts to activated myofibroblasts (Kulkarni et al., 2011).  
 
1.3. Metformin 
Metformin is a small molecule, originally developed to combat type II diabetes, is referred 
to first line medication to manage this malady. It is revealed that metformin reduces blood 
sugar level via reduction of gluconeogenesis in the liver in addition to sensitizing the cells 
to insulin (Dhatariya, 2019). Furthermore, the ability of metformin to manipulate cellular 
metabolism via deactivation of complex I in the electron transfer chain of mitochondria 
and activation of AMPK is well established (Andrzejewski et al., 2014; Loubiere et al., 
2017). Manipulation of cellular metabolism in targeted manner can bear a significant 
importance to combat a wide range of diseases such as cancer, infectious diseases, 
diseases related to function of immune system, fibrosis and etc. Since it’s well tolerated 
with very minimal side-effects, the number of reports regarding efficacy of metformin to 
efficiently manage other diseases grows rapidly. Metformin reduces ability of 
hepatocellular carcinoma cells to migrate and eventually conduct metastasis via 
activation of AMPK (Ferretti et al., 2019). Promotion of survivin degradation via 
AMPK/PKA/GSK-3β axis in the non-small cell lung cancer results in an increased level of 
apoptosis and reduced survivability of cancer cells (Luo et al., 2019). Moreover, 
metformin increases expression of brain derived neurotrophic factor in an AMPK/Tet2 
dependent manner which acts as an antidepressant (Wang et al., 2019). Its phenomenal 
effect on slowing down  the aging process and aging related diseases which is mainly 
modulated via NF-kB can’t be ignored either (Kanigur Sultuybek et al., 2019). 
Interestingly, IPF is associated with metabolic disorders. For example, a recent report has 
shown that IPF lungs display alterations in several metabolites linked to energy 
consumption (Rowzee et al., 2008). In addition, there is evidence suggesting that several 
types of lipid molecules present in blood plasma could be used as biomarkers for IPF 
(Yan et al., 2017). One study has even suggested that type 2 diabetes might be a risk 
factor for developing IPF (García-Sancho Figueroa et al., 2010). Although it remains 
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unclear whether these metabolic abnormalities represent a cause or a consequence of 
the disease, the link between fibrosis and metabolic alterations in the lung raises the 
question whether antidiabetic drugs can be good candidates for antifibrotic therapy. 
Rosiglitazone, initially developed as an antidiabetic agent. Several reports provided by us 
and other groups’ demonstrated potential efficacy of rosiglitazone to ameliorate 
progression of lung fibrosis (El Agha et al., 2017; Burgess et al., 2005). However, due to 
increased risk of heart failure in the patients suffering from ischemic heart diseases 
dramatically decreased the enthusiasm to conduct more research on antifibrotic effects 
of rosiglitazone (Castilla-Guerra et al., 2018). 
Many studies have reported the therapeutic effects of metformin in non-diabetic diseases 
such as non-small-cell lung cancer (Li et al., 2017), prostate cancer(Yu et al., 2017) and 
cardiovascular diseases (Castilla-Guerra et al., 2018). Moreover, it has been suggested 
that intraperitoneal administration of metformin attenuates bleomycin-induced lung 
fibrosis in mice via NADPH oxidase 4 (NOX4) suppression (Sato et al., 2016a). A more 
recent report has shown that metformin accelerates resolution of bleomycin-induced 
pulmonary fibrosis, suggesting activation of AMP-activated protein kinase (AMPK) as key 
underlying signaling event, leading to downregulation of alpha smooth muscle actin 
(ACTA2) and collagen, and increasing myofibroblast autophagy and ECM turnover 
(Rangarajan et al., 2018)   
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2. Objectives  
Despite ever-growing number of research reports regarding potential therapeutic targets, 
battling IPF is still very hard. The approved medications can only at best slow the disease 
progression and reduces the severity of the symptoms but don’t bear a therapeutic 
function. Hence, the lethality rate remains very high. To explore novel therapeutic 
interventions for IPF, the characteristic of activated myofibroblasts must be investigated. 
Better characterization of activated myofibroblasts and their origin will help to improve 
current understanding of the disease progression and pathogenesis. An 
underappreciated population of cells which have been over looked for a long time is 
pulmonary lipofibroblasts.  However, to study potential contribution of lipofibroblasts to 
the pool of activated myofibroblasts, one must first study and better characterize the 
lipofibroblasts themselves.  
This study provides a better characterization of lipofibroblast in the mouse model, time 
course of their formation in the murine lung in addition to providing evidence regarding 
involvement of Fgf10 signaling in their formation. Furthermore, using lineage tracing, their 
contribution to the pool of activated myofibroblasts has been explored. Last but not least, 
effect of metformin in reversing pulmonary fibrosis via trans-differentiation of activated 
myofibroblast to lipofibroblasts due to enforcing the lipogenic metabolomics changes. Has 
been studied.  
This study contains two main goals as described below: 
I. Better characterization of lipofibroblasts and investigating their 
contribution to pool of activated myofibroblasts. 
Using mouse model, formation of lipofibroblasts during the embryonic development was 
explored utilizing different readouts such as quantitative-PCR and flow cytometry. 
Staining of the single cell suspension prepared from mouse lung provided opportunity to 
investigate formation of lipofibroblasts based on existence of lipid droplets which indicates 
full differentiation status. Furthermore, cell culture and Fgfr1b knock out animals were 
used to study status of Fgf10 signaling in the formation of these cells. Labeling of 
lipofibroblasts using AdrpCre-ERT2; mT/mG mice before bleomycin injury provided 
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possibility to study fate of preexisting lipofibroblasts during progression of fibrosis and 
resolution phase.  
II. Trans-differentiation of activated myofibroblasts to lipofibroblasts can be 
a novel therapeutic intervention 
TGFβ1 signaling is considered to be the most important signaling cascade in the 
progression of fibrosis. Treatment of pulmonary fibroblasts with recombinant TGFβ1 
results in trans-differentiation of these cells to activated myofibroblasts. Rosiglitazone, an 
agonist of Pparg, can activate Pparg signaling pathway which will counterbalance 
activation of TGFβ1 pathway. Since rosiglitazone might not be the ideal therapeutic option 
for patients who are at risk of developing ischemic heart disease, exploring the 
applicability of alternative therapeutic compounds is clinically relevant. Thus in search for 
an alternative antidiabetic drug, it was hypothesized that metformin accelerates fibrosis 
resolution by inducing lipogenic differentiation in lung fibroblasts, while inhibiting TGFβ1-
mediated myogenic differentiation. To test this hypothesis, primary cultures of human IPF-
derived lung fibroblasts, cultures of precision-cut lung slices (PCLS) derived from human 
IPF patients, and genetic lineage tracing in the context of the bleomycin injury model of 
lung fibrosis in mice were used.  
 
The objectives of this study are summarized below: 
 Better characterizations of lipofibroblasts during embryonic development in the 
murine model 
 Exploring importance of FGF10 signaling in the formation of lipofibroblasts 
 Studying possible transdifferentiation of lipofibroblasts to activated myofibroblasts 
during progression of fibrosis.  
 Investigating efficacy of metformin to reverse pulmonary fibrosis via enforcing 
lipogenic phenotype in the activated myofibroblasts  
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3. Materials and Methods 
3.1.  Animal experiments 
All animals were housed under specific pathogen-free (SPF) conditions with free access 
to food and water. Acta2-CreERT2 (STOCK_Tg(Acta2-cre/ERT2)12Pcn) mice were 
kindly provided by Dr. Pierre Chambon (University of Strasbourg, France). In this 
transgenic line, CreERT2 coding sequence was inserted at the initiation codon of Acta2 
in a mouse bacterial artificial chromosome (BAC) (MGI: 3831907). The Cre reporter line 
tdTomatoflox (B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J was purchased from the 
Jackson laboratory (stock number 007909). RjOrl:SWISS also known as CD1 line were 
purchased from Janvier labs. AdrpCre-ERT2 knock-in mice (knock in of Cre-ERT2 in 
Exon 8 of the endogenous Adrp locus) were generated at the Max Planck Institute in Bad 
Nauheim, Germany (A.N., unpublished data) and the experiments performed in 
collaboration with Aglaia Ntokou, Friederike Klein and Katrin Ahlbrecht (Morty lab in MPI Bad 
Nauheim). Tandem dimer Tomato (tdTomatoflox) and membrane-targeted 
tdTomato/membrane-targeted green fluorescent protein (mT/mG) Cre-reporter mice were 
purchased from the Jackson laboratory. 
 
3.2. Animal experimentation approval  
Animal experiments were approved by the local authorities (Austrian Ministry of 
Education, Science and Culture; BMWFW-66.010/0043-WF/V/3b/2016), local authorities 
in Bad Nauheim, Germany (protocol number B2/354) and Justus Liebig University 
Giessen 405_M and performed in accordance with the EU directive 2010/63/EU. 
 
3.3. Mice Genotyping  
Tissues from the distal tip of the tails were digested in 200 l Viagen including 1 l 
proteinase K in 55°C on a shaker overnight, then reaction was stopped in 85°C for 40 
min. Genotyping was done by PCR. For protocol and primer sequences please see Table 
1. PCR products were analyzed using a 1,5 % agarose gel containing TAE buffer with 
Sybrsafe (50 l Sybrsafe + 500 ml 1x TAE buffer). 10 l of PCR samples was loaded with 
2 l loading dye (Biorad Nucleic Acid Sample loading buffer, 5x), and then gel was run 
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with 120V for 30-45 min. A molecular ladder (QX Size Marker, 100bp-2.5kb, Qiagen) was 
used to detect the expected band sizes (Table 1). 
Table 2. Primer sequences and protocols for genotyping. 
Mouse Line Primer sequence PCR Protocol 
Step Temp. 
(ₒC) 
Time 
Acta2-CreERT2 1) ATT TGC CTG CAT TAC 
CGG TC  
 
 
2) ATC AAC GTT TTG TTT 
TCG GA 
1 94 30 
sec 
2 94 30 
sec 
3 55 30 
sec 
4 (repeat 
Step 2-4 
30 times 
total) 
72 1 min 
5 4 hold 
tdTomatoflox 1) CTG TTC CTG TAC GGC 
ATG G  
2) GGC ATT AAA GCA GCG 
TAT CC  
3) CCG AAA ATC TGT GGG 
AAG TC  
4) AAG GGA GCT GCA 
GTG GAG TA 
1 94 3 min 
2 94 20 
sec 
3 61 30 
sec 
4 (repeat 
Step 2-4 
30 times 
total) 
72 30 
sec 
5 72 2 min 
6 4 hold 
AdrpCre-ERT2 1) GGT GCA AGC TGA ACA 
ACA GG 
1 94 3 min 
2 94 30 
sec 
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2) GGT CCT GCC AAT GTG 
GAT CA 
3 57.3 45 
sec 
4 (repeat 
Step 2-4 
40 times 
total) 
72 1 min 
5 72 10 
min 
6 4 hold 
(mT/mG) 1) CCA GGC GGG CCA 
TTT ACC GTA AG 
2) AAA GTC GCT CTG 
AGT TGT TAT 
3) GGA GCG GGA GAA 
ATG GAT ATG 
1 94 2 min 
2 94 20 
sec 
3 -0.5 ₒC 
per cycle 
decrease 
65 15 
sec 
4 (repeat 
Step 2-4 
10 times 
total) 
68 10 
sec 
5 94 15 
sec 
6 60 15 
sec 
7 (repeat 
Step 5-7 
28 times 
total) 
72  10 
sec 
8 72 2 min 
9 4 hold 
 
Table 3. Expected band size of genotyping products. 
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Mouse line  Expected band size for WT Expected band size for 
mutant 
Acta2-CreERT2  - 349 bp 
tdTomatoflox 297 bp 196 bp 
AdrpCre-ERT2 - 463 bp 
(mT/mG) 603 320 bp 
 
3.4.   Bleomycin injury, tamoxifen administration and metformin 
treatment  
At 11-12 weeks of age, Acta2-CreERT2; tdTomatoflox males were subjected to 
intratracheal instillation of saline or bleomycin (0.8 U/kg body weight) (Sigma-Aldrich) 
using a micro-sprayer (Penn-Century, Inc.) at the Ludwig Boltzmann Institute in Graz, 
Austria. Five days after bleomycin instillation, mice were fed tamoxifen-containing chow 
(400 mg/kg food, Envigo) for nine days. Metformin (1.5 mg/mL) or vehicle (PBS) was 
supplied via drinking water at day 14 after bleomycin instillation. Lungs were harvested 
on day 28.   
AdrpCre-ERT2; mT/mG mice were fed tamoxifen-containing pellets starting day -28 until 
day -14 followed by 14 dyas of normal food (as chase period). Tamoxifen-containing 
pellets (0.4 g tamoxifen per Kg of pellets) were purchased from Altromin. At day 0, the 
animals received an intratracheal instillation of saline or bleomycin (3.5 U/Kg of body 
weight) at the Max Planck Institute in Bad Nauheim, Germany and were sacrificed at day 
14.  
 
3.5.   Mouse primary cell culture 
 Whole lungs were dissected from embryos, minced into small pieces and subjected to 
0.5% collagenase IV (Gibco)(45 min at 37°C) digestion to give rise to single cells. In the 
next step cell suspension passed through 70 and 40 micrometer cell strainers, 
respectively. Following centrifugation (1000 RPM, 10 minutes), cells were resuspended 
and plated in 6-well plates for 17 minutes in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Invitrogen) supplemented with 10% bovine calf serum (BCS, Gibco) at 37 °C and 5% 
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CO2. Due to difference in adhesion capacity of the epithelial and mesenchymal cells, 
mesenchymal cells will attach to plate while the epithelial and other cell are mostly floating 
in the media. After 17 minutes, the plates were washed with pre-warmed PBS. Medium 
was replaced with fresh Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen) 
supplemented with 10% bovine calf serum (BCS, Gibco) and incubated at 37 °C and 5% 
CO2 for next 24 hours.  
 
3.6.   Human-derived specimens 
Fresh human lung explants and primary lung fibroblasts were obtained through the 
European IPF registry (eurIPFreg) at the Universities of Giessen and Marburg Lung 
Center, member of the German Center for Lung Research. Written consent was obtained 
from each patient and the study was approved by the ethics committee of Justus-Liebig 
University Giessen. 
 
3.7.  Human cell culture 
Primary lung fibroblasts derived from twelve IPF patients were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Invitrogen) supplemented with 10% bovine calf serum 
(BCS, Gibco) at 37 °C and 5% CO2. Cells between passages 3 and 7 were used for the 
experiments. Briefly, 3x105 cells were seeded per well in 6-well plates (Greiner Bio-One). 
The next day, cells were starved (0% serum) for 24 h and then treated with different 
compounds. For imaging experiments, cells were cultured in 4-well chamber slides 
(Sarstedt) at a density of 75,000 cells per well and were treated according to the same 
procedure described above. Cells were treated with metformin (Ratiopharm), pirfenidone 
(Cayman Chemical Company), nintedanib, selumetinib or GSK621 (all from 
Selleckchem), recombinant human TGFβ1 (rhTGFβ1) or rhBMP2 (both from R&D 
Systems). Table 3 summarizes treatment conditions. As controls, the same cells were 
treated with the corresponding solvents as recommended by the manufacturer (same 
volumes as treated groups). 
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Table 4. Treatment conditions of primary human lung fibroblasts. 
Compound  Final concentration Solvent 
GSK621 10 µM* DMSO 
Metformin 1 mM, 5 mM,10 mM DMEM 
Nintedanib 1 µM* DMSO 
Pirfenidone 0.3 mg/mL* Ethanol  
Selumetinib 5 µM* DMSO 
rhTGFβ1 2 ng/mL rhTGFβ1 reconstitution buffer 
rhBMP2 50 ng/mL* rhBMP2 reconstitution buffer 
* Dosage was chosen based on a literature search and the dose showing highest efficacy 
was selected. 
 
3.8.  Precision-cut lung slices 
Fresh lung specimens were obtained from 4 IPF patients that underwent lung 
transplantation. Precision-cut lung slices were prepared in two ways: lung specimens 
were cut into strips (length: 2-3 cm, thickness: 3-5 mm) and later chopped into 200 µm-
thick slices using a McIlwain Tissue Chopper (Campden Instruments Ltd.); or lung tissues 
were gently injected with 1.5% low-melting agarose (Roth) and cut using a vibratome 
(Thermo Fisher Scientific) into 400 µm-thick slices. Five to six PCLS were cultured in 5 
mL of DMEM supplemented with 10% BCS at 37 °C and 5% CO2 for five days. Cultures 
were treated with different agents at the beginning of the culture process (without 
starvation). 
 
3.9.   siRNA transfection 
siGENOME PRKAA1 siRNA (D-005027-01-0002), siGENOME PPARg siRNA (D-
003436-03-0005), and the corresponding scrambled siRNA (siGENOME Non-Targeting 
siRNA #2 (D-001210-02-05)) were obtained from Dharmacon. When cells reached 50-
60% confluence in 6-well plates, they were transfected using lipofectamine RNAiMAX 
(Invitrogen) according to manufacturer’s instructions (25 pmol per well, 7.5 µL 
lipofectamine per well). The culture medium was replaced 24 h after transfection. 
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Seventy-two hours after transfection, the culture medium was replaced by either fresh 
medium or fresh medium supplemented with 5 mM metformin or BMP2. After 72 h, cells 
were harvested for protein or RNA extraction. 
 
3.10. RNA extraction and quantitative real-time PCR 
Total RNA extraction was performed using RNeasy mini or micro kits (Qiagen) and cDNA 
synthesis was carried out using Quantitect reverse transcription kit (Qiagen) according to 
manufacturer’s instructions. Quantitative real-time PCR (qPCR) was performed using 
PowerUp SYBR green master mix (Applied Biosystems) and LightCycler 480 II machine 
(Roche Applied Science). Porphobilinogen deaminase (PBGD) was used as a reference 
gene. Data are presented as expression levels relative to PBGD using the 2-ΔCT method. 
Primer sequences are shown in Table 4. 
 
 Table 5. Primer sequences for qPCR. 
Gene 
name 
(human) 
Forward-primer sequence  Reverse-primer sequence  
COL1A1 ATGTTCAGCTTTGTGGACCTC CTGTACGCAGGTGATTGGTG 
PBGD TGTCTGGTAACGGCAATGCG CCCACGCGAATCACTCTCAT 
PLIN2 TCAGCTCCATTCTACTGTTCACC CCTGAATTTTCTGATTGGCAC  
PPARg TTGCTGTCATTATTCTCAGTGGA GAGGACTCAGGGTGGTTCAG 
Gene 
name 
(mouse) 
Forward-primer sequence  Reverse-primer sequence  
Fgf10 ATGACTGTTGACATCAGACTCCTT CACTGTTCAGCCTTTTGAGGA 
Pparg GAAAGACAACGGACAAATCACC GGGGGTGATATGTTTGAACTTG 
Adrp CCTCAGCTCTCCTGTTAGGC CACTACTGCTGCTGCCATTT 
Fgfr2b CCCTACCTCAAGGTCCTGAA CATCCATCTCCGTCACATTG 
Fgfr1b CCACAGGTCTGGTGACAGTGA CGGGAATTAATAGCTCGGATG 
Hprt GCTGACCTGGATTAC TTGGGGCTGTACTGCTTA 
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3.11. Protein extraction and Western blotting 
Total protein lysates were prepared using RIPA buffer (Santa Cruz) according to 
manufacturer’s instructions. Proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) followed by blotting on polyvinylidene 
fluoride (PVDF) membranes (Thermo Fisher Scientific) using Trans-Blot SD semi-dry 
transfer cell (Bio-Rad Laboratories). Antibodies against AMPK (Abcam, 1:2500), PPARγ 
(H-100) (Santa Cruz, 1:1000), phospho-(Ser112)-PPARγ (Merck Millipore, 1:500), p44/42 
mitogen-activated protein kinase (MAPK, a.k.a. extracellular signal-regulated kinases 1 
and 2, ERK1/2) (Cell Signaling, 1:1000), phospho-p44/42 MAPK [(ERK1) 
(Tyr204)/(ERK2) (Tyr187) (D1H6G)] (Cell Signaling, 1:1000) and cleaved poly(ADP-
ribose) polymerase 1 (PARP1) (Abcam, 1:2000) were used overnight at 4°C. Beta-actin 
(ACTB) was used as a loading control (Biolegend, 1:2500). HRP-conjugated anti-rabbit 
IgG (Promega, 1:5000), HRP-conjugated anti-mouse IgG (H+L) (Promega, 1:5000) and 
HRP-conjugated anti-rat IgG (Biolegend, 1:5000) were used as secondary antibodies for 
1 h at room temperature (RT). Subsequently, membranes were covered with AceGlow 
chemiluminescence substrate (Peqlab) and imaged immediately using ChemiDoc XRS+ 
(Bio-Rad Laboratories). 
 
3.12. Staining for lipid-droplet accumulation 
For time-lapse imaging, live cells were treated with different agents and HCS LipidTOX 
red neutral lipid dye (Invitrogen, 1:200) was immediately added. Cells were then placed 
in the incubation chamber (37 °C and 5% CO2) of DMI6000 B live imaging microscope 
(Leica). Images were acquired every 1 h. In other cases, cells were fixed using 2% 
paraformaldehyde (PFA, Roth) for 20 min followed by washing with PBS (Gibco). A 
mixture of diluted LipidTOX (1:200) and Hoechst (1:5000) in PBS was then used to stain 
fixed cells. Subsequently, slides were mounted using ProLong Gold Antifade Reagent 
(Molecular Probes). 
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3.13. Hematoxylin and Eosin staining 
Human-derived PCLS or mouse lung tissues were fixed using 4% PFA followed by 
embedding in paraffin. Paraffin blocks were sectioned into 5 µm-thick slices and placed 
on glass slides. Following deparaffinization, lung sections were stained with hematoxylin 
(Roth) for 2 min, washed with running tap water for 10 min and then stained with eosin 
(Thermo Fisher Scientific) for 2 min.  
3.13.1. Deparaffinization process  
Slides will be placed in the jars with specified reagents in the following orders. 
 Xylol (6 minutes)  
 Xylol (6 minutes) 
 100% Ethanol (2minutes) 
 100% Ethanol (2 minutes) 
 95% Ethanol (2 minutes) 
 70 % Ethanol (2minutes) 
 50% Ethanol (2minutes) 
 30% Ethanol (2minutes) 
 Deionized water (2minutes) 
 
3.14. Masson’s trichrome staining and fibrosis quantification 
Collagen staining was performed using Masson’s trichrome staining kit according to the 
protocol recommended by the manufacturer (Thermo Fisher Scientific). Fibrosis was 
assessed by semi-automated quantification using VIS Image Analysis Software 
(Visiopharm). In brief, the algorithm calculates the percentage of the area covered by 
collagen fibers relative to the area covered by lung tissue (excluding airways and 
airspaces). 
 
3.15. Total collagen assay 
In order to assess total collagen levels, 10 mg of each tissue sample was subjected to 
the total collagen assay kit according to manufacturer’s instructions (Biovision).    
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3.16. Immunofluorescence 
3.16.1. COL1a1 staining 
Following deparaffinization, slides underwent antigen retrieval using citrate buffer (Vector 
Laboratories) for 15 min followed by cooling on ice for 20 min. Slides were then blocked 
with 3% bovine serum albumin (BSA, Jackson Immunoresearch Laboratories) in PBS for 
1h at RT. Anti-collagen 1 A1 (anti-COL1A1) antibodies (Rockland, 1:200) and goat anti-
rabbit antibodies (Life Technologies, 1:500) were used for immunofluorescence. Slides 
were finally mounted with ProLong Gold Antifade Reagent containing DAPI (Molecular 
Probes). 
3.16.2. Staining for ACTA2 and PLIN2 
Following deparaffinization, slides were blocked with 3% BSA solution in PBS with 0.4% 
Triton-X (Sigma-Aldrich) for 1h at RT. Next, either rabbit anti-ADFP antibody (Abcam, 
1:250) (overnight at 4°C) or mouse FITC-conjugated anti-alpha smooth muscle actin 
antibody (Sigma, 1:200) (overnight at 4°C) and goat anti-rabbit antibodies (Life 
Technologies, 1:500) (Ih at RT) were used for immunofluorescence. Slides were finally 
mounted with ProLong Gold Antifade Reagent containing DAPI (Molecular Probes). 
3.16.3. Staining PCLSs  
Human PCLS were fixed in 4% PFA for 2 h and stored in PBS containing 0.02% sodium 
azide. Fixed PCLS were blocked with 3% BSA in PBS for 2 h at RT, stained with anti-
COL1A1 antibodies (Rockland, 1:200) overnight at 4°C and washed with PBS (three 
times, 30 min each). A mixture of Alexa Fluor 488-conjugated anti-rabbit antibodies 
(Invitrogen, 1:200), HCS LipidTOX red neutral lipid dye (Invitrogen, 1:200) and Hoechst 
(1:5000) was added for 3 h at RT. After washing, PCLS were placed in glass-bottomed 
4-well micro slides (Ibidi) containing PBS and imaged by confocal microscopy (Leica TCS 
SP5). 
 
3.17. Flow Cytometry  
Cultured fibroblasts were washed with PBS and resuspended in PBS containing LipidTOX 
(1:200). Following incubation for 30 min, cells were subjected to flow cytometry using 
Accuri C6 (BD Biosciences). Cultured PCLS and/or finely minced mouse lung tissues 
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underwent digestion with 0.5% collagenase (Gibco) in PBS for 45 min at 37 °C while 
rotating. Cell suspensions were then aspirated through 18, 20, 24 G needles and passed 
through 70- and 40-µm cell strainers (Greiner Bio-One). Cells were pelleted, resuspended 
in PBS and stained with anti-CD45 (Biolegend, 1:100), CD31 (Biolegend, 1:100) and 
CD326 (EpCAM, Biolegend, 1:50) antibodies, as well as LipidTOX (1:200). Stained cell 
suspensions were then analyzed using LSRFortessa (BD Biosciences). Data were 
analyzed using FlowJo software (FlowJo, LLC). 
 
3.18. Gene expression microarrays 
Total RNA Cy5-labeling was carried out using the LIRAK kit (Agilent Technologies) 
according to manufacturer’s instructions. Per reaction, 200 ng of total RNA was used. Cy-
labeled aRNA was hybridized overnight to 8 x 60K 60mer oligonucleotide-spotted 
microarray slides (Agilent Technologies, design ID 028005). Hybridization and 
subsequent washing and drying of the slides were performed following the Agilent 
hybridization protocol. Dried slides were scanned at 2 µm/pixel resolution using the 
InnoScan is900 (Innopsys). Image analysis was performed using Mapix 6.5.0 software 
and calculated values for all spots were saved as GenePix results files. Stored data were 
evaluated using the R software and the limma package from BioConductor. Log mean 
spot signals were taken for further analysis. Data were quantile-normalized before 
averaging. Genes were ranked for differential expression using a moderated t-statistic. 
Pathway analyses were done using gene set tests on the ranks of t-statistics. 
 
3.19. Kinase activity assay 
Kinase activity of metformin- or vehicle-treated IPF fibroblasts (n=3 per group) was 
analyzed by the PamStation (PamGene International BV) that uses a methodology that 
allows robust analysis of the activity of tyrosine as well as serine/threonine kinases in 
cells and tissues(Anderson et al., 2015, 2016; Arsenault et al., 2011; Piersma et al., 
2010). Hereby, active kinases phosphorylate their distinct peptide substrates presented 
on a peptide array chip. Phosphorylated peptides are recognized by phospho-specific 
FITC-labeled antibodies and detection, performed in multiple cycles at different exposure 
times, is monitored by a CCD camera. Software-based image analysis integrates the 
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signals obtained within the time course of the incubation of the kinase lysate on the chip 
into one single value for each peptide for each sample (exposure time scaling). Log 
transformation of processed signals allows easier graphical presentation of the raw data. 
Thereby, data with significant differences in intensity are visualized on the log-
transformed y-axis in a heat map that shows the degree of phosphorylation for each 
peptide. 
 For protein isolation including active kinases, IPF fibroblasts were washed with 5 mL ice-
cold PBS and scraped from the dishes in 100 µL of M-PER lysis buffer (Thermo Fisher 
Scientific) containing protease and phosphatase inhibitor cocktails (Pierce). The lysate 
was incubated for 1 h at 4°C with constant agitation followed by centrifugation at 16,000 
g for 15 min at 4°C. The supernatant was immediately flash-frozen in liquid nitrogen and 
stored at -80°C. Protein concentration was determined using a bicinchoninic acid (BCA) 
protein assay kit (Thermo Fisher Scientific) according to manufacturer’s instructions. 
 For tyrosine kinase activity detection, 10 µg of protein lysate was dispensed onto an array 
of the PamChip PTK (phospho-tyrosine kinase) dissolved in protein kinase buffer and 
additives (proprietary information) including 1% BSA, 10 mM DTT, 0.6 µL FITC-
conjugated antibodies and 400 µM ATP in a final volume of 40 µL (assay master mix). A 
total of 1 µg of protein lysate was used for serine/threonine kinase activity detection on 
an array of the PamChip STK (serine/threonine kinase) with protein kinase buffer 
(proprietary information) supplied with 1% BSA, 0.46 µl primary STK antibody mix and 
400 µM ATP (sample mix). After an initial incubation time, secondary FITC-labeled 
antibodies (0.4 µL) were added. The mixture was dissolved in antibody buffer (proprietary 
information) and water in a final volume of 30 µL (detection mix). 
 Upstream kinase prediction on the basis of the different phosphorylation pattern in 
metformin- and vehicle-treated IPF fibroblasts was conducted using the Bionavigator 
software v.6.3.67.0 (PamGene International). 
 
3.20. Statistical analyses 
Statistical analyses and graph assembly were carried out using GraphPad Prism 6 
(GraphPad Prism Software). To assess the normal distribution of data sets, D’Agostino-
Pearson normality test was applied. In case of normal distribution, Student’s t-test 
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(unpaired, two-tailed) was utilized to compare the means of two groups, while one-way 
ANOVA (with post-hoc tests) was used to compare the means of three or more groups. 
In the cases where data were not normally distributed, respective non-parametric tests 
were applied (Mann-Whitney test to compare the means of two groups and Kruskal-Wallis 
test to compare the means of three or more groups). Data are presented as mean ± SEM. 
The number of biological samples (n) for each group and the utilized statistical tests are 
stated in the corresponding figure legends. Differences in means were considered 
statistically significant if P<0.05. 
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4. Results 
4.1. PART І. Characterization of murine lipofibroblasts and 
involvement of fibroblast growth factor 10 in formation of them  
4.1.1.  Lipofibroblast formation increases progressively during embryonic 
lung development 
Since emergence of LIFs in the embryonic mouse lung was unexplored, first aim was to 
quantify the relative number of lipid-droplet containing cells between E13.5 and E18.5 
using LipidTOX staining followed by flow cytometry. LipidTOX is a dye that labels neutral 
lipids that are abundantly present in LIFs. Our results represent that LipidTOX+ cells 
appeared at late pseudoglandular stage, between E15.5 and E16.5, and their count can 
be as high as 30% of the total cell count in the developing lung (Fig. 1A, B). Next, the 
expression levels of adipogenic markers such as Plin2, Pparg and Fgf10 were assessed 
in the lung homogenate qPCR (Fig. 1C). Expression level of Plin2 was very low levels 
between E11.5 and E15.5 and started to upregulate beginning at E16.5, peaking at E18.5. 
Pparg expression was first detected at E15.5 and increased progressively up to E18.5. 
Our data revealed Steady increase of Fgf10 expression from E11.5 to E18.5. 
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Figure 1. Lipofibroblasts emerge in the mouse lung during the late 
pseudoglandular stage.  
(A) FACS analysis of LipidTOX-stained cell suspensions from embryonic CD1 lungs. 
(B) Quantification of the FACS plots shown in A (n=4 per stage). (C) qPCR analysis 
showing the expression patterns of Pparg, Plin2 and Fgf10 during embryonic lung 
development (n=3 per stage).  
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4.1.2. Increasing level of Fgf10 receptors and lipogenic markers expression 
in lung fibroblasts  
In order to dive deeper in the possible role of Fgf10 in formation of lipofibroblasts and any 
possible contribution of epithelial cell in formation of LIFs, primary lung mesenchyme was 
cultured at different embryonic stages (E14.5-E18.5). Following differential adhesion, 
mesenchymal cells allowed to grow for 24 h before RNA isolation (Fig. 2A). Minimal 
epithelial contamination of cell culture has been confirmed via Cdh1 IF (Fig. 2B). qPCR 
revealed low expression levels for Pparg (Fig. 2D) and Plin2 (Fig. 2E) at E14.5 and E15.5 
with increased expression levels between E16.5 and E18.5. This is consistent with the 
data obtained with lung homogenates (Fig. 1C), thus indicating upregulation of Pparg and 
Plin2 in the lung mesenchyme during late embryonic stages. Parallel to the increase in 
LIF markers, Fgf10 expression was also increased in late embryonic stages (Fig. 2C). 
Strikingly, Fgfr2b and Fgfr1b, the genes encoding the two Fgf10 receptors, were 
upregulated in late embryonic lung mesenchyme, with the increase in Fgfr2b expression 
preceding that observed for Fgfr1b (Fig. 2F, G). 
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Figure 2. Increasing level of lipogenic markers coincides with increasing level of 
Fgf receptors in the lung.  
(A) Time line for harvesting embryonic lungs and the subsequent cell culture plan. (B) 
IF for Cdh1 showing minimal epithelial contamination in the primary culture of 
embryonic lung mesenchyme. (C-G) qPCR analysis for Fgf10, Pparg, Plin2, Fgfr2b and 
Fgfr1b. 
 
4.1.3. Fgfr2b compensates loos of Fgfr1b function in formation of 
lipofibroblasts 
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Increased mesenchymal expression of Fgfr1b and Fgfr2b in the late stage of lung 
development in parallel to formation of lipofibroblasts raised the question whether these 
two receptors play a functional role in this process. Thus, we investigated the phenotype 
and status of lipofibroblasts in the Fgfr1b knockout animals. First, the phenotype of E18.5 
Fgfr1b knockout lungs was examined, and analysis by qPCR confirmed the absence of 
Fgfr1b expression in knockout lungs (n=4) compared with control lungs (n=7; Fig. 4A). 
Hematoxylin and Eosin (H&E) staining did not show any apparent phenotype in knockout 
lungs compared with control lungs (Fig. 3H, I versus F, G). Interestingly, qPCR analysis 
showed that Pparg was significantly increased in the knockouts compared with controls 
(Fig. 3C), and this was accompanied by a modest increase in Plin2 expression (Fig. 3D). 
Surprisingly, Fgfr2b expression was increased (Fig. 3E), whereas Fgf10 expression levels 
remained unchanged (Fig. 3B). 
Investigating the protein levels of Plin2 by IF revealed a slight increase in Plin2 
immunoreactivity in the knockouts (Fig. 3L, M) compared with controls (Fig. 3J, K). 
Quantification of the Plin2 signal using MetaMorph software showed a trend towards an 
increase in the number (Fig. 3N) and area (Fig. 3O) of Plin2 immunoreactive spots in 
knockout lungs (n=3) compared with control lungs (n=3). Our results therefore indicate 
that ubiquitous deletion of Fgfr1b in the lung does not compromise LIF formation during 
embryonic development; instead, there is a trend towards increased LIF formation. 
Interestingly, the elevated levels of Fgfr2b in Fgfr1b knockout lungs suggest that Fgfr2b 
could be compensating for the loss of Fgfr1b, thereby allowing normal and even 
enhanced LIF formation. 
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Figure 3. Fgfr1b knockouts suggest compensation with Fgfr2b. 
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(A-E) qPCR analysis of Fgfr1b, Fgf10, Pparg, Plin2 and Fgfr2b in Fgfr1b−/− lungs 
compared with littermate controls. (F-I) H&E staining showing no apparent histological 
differences between control (F, G) and Fgfr1b knockout lungs (H, I). (J-M) IF for Plin2 
showing a slight increase in immunoreactivity in Fgfr1b knockout lungs (L, M) compared 
with control lungs (J,K). (N, O) Quantification of Adrp immunoreactivity using 
MetaMorph software. Scale bars: 200 µm in F, H; 25 µm in G, I, K, M; 50 µm in J, L. 
(A-E) Fgfr1b+/+, n=7; Fgfr1b−/−, n=4. (N, O) Fgfr1b+/+, n=3; Fgfr1b−/−, n=3. 
 
4.2. Part II. Lipofibroblasts are a source of activated myofibroblasts in 
lung fibrosis  
 
4.2.1. Lipofibroblasts give rise to activated myofibroblasts during fibrosis 
formation 
To test whether lipofibroblasts contribute to the activated myofibroblast pool during 
fibrosis formation, pre-existing lipofibroblasts were labeled using a recently 
generated AdrpCre-ERT2  knock-in mouse line followed by bleomycin injury (Fig. 
4A). AdrpCre-ERT2 ; mT/mG mice were fed tamoxifen-containing pellets for 2 weeks 
followed by 2 weeks of normal pellets before being challenged with either saline or 
bleomycin (Fig. 4B).  Immunofluorescent staining showed minimal co-localization of the 
lineage label (mGFP) and ACTA2 in saline-treated lungs at 14 d.p.i. (Day Post Instilation) 
(Fig. 4C-G). In contrast, mGFP+ cells were located in dense fibrotic areas where 
ACTA2+ myofibroblasts were also aggregated in bleomycin-treated lungs (Fig. 4H-L). 
FACS analysis was used to quantify the contribution of lipofibroblasts to activated 
myofibroblast formation (Fig. 4M-O). To restrict the analysis to resident fibroblasts, 
hematopoietic, endothelial and epithelial cells were excluded from the analysis. The 
results showed that our lineage-tracing tool labeled 27.2%–34.8% of 
LipidTOX+ fibroblasts in the lung (Fig. 4V) in parallel to a dramatic decrease in the number 
of LipidTOX+ cells after bleomycin injury (from 9.4% to 1.5%) (Fig. 4T), hinting at a 
lipofibroblast-to-activated-myofibroblast transdifferentiation. An increase in the number of 
ACTA2+ cells from 2.3% to 5.7% was observed upon bleomycin injury (Fig. 4P), 
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concomitantly with an increase in the number of mGFP+ cells that co-stained for ACTA2 
(Fig. 4R) and a decrease in the number of mGFP+ that co-stained for LipidTOX (Fig. 4U). 
Interestingly, while the number of lineage-labeled cells remained unchanged (Fig. 4Q), 
these cells contributed to 19.7% of the total ACTA2+ cells in bleomycin-treated lungs (Fig. 
4S). Sorted mGFP+ cells by FACS were subjected to gene expression analysis by qPCR. 
Activated myofibroblast markers (Acta2 and Col1a1) were drastically upregulated in 
lineage-labeled cells derived from fibrotic lungs compared to control lungs (7.8-fold and 
35.1-fold, respectively) (Fig. 4W, X), indicating that these cells acquired an activated 
myofibroblast phenotype. Fgf10 was also significantly upregulated (3-fold) in lineage-
labeled cells upon bleomycin treatment (Fig. 4Y). 
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Figure 4. Lipofibroblasts contribute to the pool of activated myofibroblasts 
during fibrosis formation  
(A) Schematic representation of the AdrpCre-ERT2 and mT/mG constructs. (B) 
Timeline of tamoxifen and saline or bleomycin treatments. Mice were fed tamoxifen-
containing pellets before saline or bleomycin was administered intratracheally. Lungs 
were harvested at 14 d.p.i. (C–F) Immunofluorescent staining of saline-treated lungs 
showing DAPI, mGFP, and ACTA2 single channels in addition to a merged image. (G) 
A high-magnification image of the region marked by the box in the merged image (F). 
(H–K) Immunofluorescent staining of bleomycin-treated lungs showing DAPI, mGFP, 
and ACTA2 single channels in addition to a merged image. (L) A high-magnification 
image of the region marked by the box in the merged image (K). (M–O) Gating strategy 
for the detection of ACTA2+, LipidTOX+, and mGFP+ cell populations by FACS. (P–V) 
FACS-based quantification of ACTA2+, mGFP+, and LipidTOX+ cell populations at 14 
d.p.i. (W–Y) qPCR for Acta2, Col1a1, and Fgf10 on mGFP+ cells sorted from saline- 
and bleomycin-treated lungs at 14 d.p.i. Scale bar: 25 μm. SAL d14, n = 3; BLM d14, n 
= 3–4; n represents biological replicates 
 
4.2.2. Activation of Pparg signaling antagonizes TGFβ1-mediated fibrogenic 
response 
In order to investigate whether TGFβ1 activity in IPF fibroblasts can be suppressed via 
activation of PPARg signaling and reinforcing the lipogenic phenotype, human lung 
fibroblasts were cultured in the presence of the PPARg agonist rosiglitazone (20 μM) 
and/or recombinant TGFβ1 (1 ng/mL), and cells were harvested after 72 hr for qPCR 
analysis (Fig. 5). TGFβ1 treatment strongly inhibited PPARg (Fig. 5A) 
and PLIN2 expression (Fig. 5B) (18.6-fold and 6.8-fold downregulation, respectively) and 
upregulated ACTA2 (Fig. 5C) and COL1A1 expression (Fig. 5D) (7-fold and 9.5-fold, 
respectively) compared to the control group. Interestingly, rosiglitazone treatment 
significantly upregulated PLIN2 expression (3.3-fold compared to the control group) and 
attenuated its downregulation by TGFβ1 (Fig. 5B) (with 2.9-fold upregulation in the 
TGFβ1+Rosi group compared to the TGFβ1-treated group). In parallel to the inhibition of 
TGFβ1-mediated downregulation of lipogenic markers, rosiglitazone treatment 
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significantly attenuated TGFβ1-mediated upregulation of myogenic 
markers ACTA2 and COL1A1 (Fig. 5C, D) (with 2.2-fold and 1.25-fold downregulation, 
respectively, in the TGFβ1+Rosi group compared to the TGFβ1-treated group). 
  
Figure 5. Rosiglitazone attenuates TGFβ1-mediated fibrogenesis via 
reinforcement of the lipogenic phenotype in human lung fibroblasts. 
following starvation for 24 hours cells were treated with 1 ng/mL recombinant TGFβ1 
and/or 20 μM rosiglitazone. After 72 hours, cells were harvested and gene expression 
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was analyzed by qPCR. (A) TGFβ1 strongly inhibits PPARg expression. (B) 
Rosiglitazone induces the expression of PLIN2 and attenuates TGFβ1-mediated 
downregulation. (C and D) TGFβ1 significantly upregulates ACTA2 and COL1A1 and 
rosiglitazone attenuates this effect. Rosi, rosiglitazone. Control, n = 18–23; TGFβ1, n = 
15–22; Rosi, n = 15–23; TGFβ1+Rosi, n = 15–24; n represents biological replicates. 
 
4.3. Part III. Metformin induces lipogenic differentiation in 
myofibroblasts to reverse mouse and human lung fibrosis 
 
4.3.1. Metformin induces lipid-droplet accumulation in human IPF lung 
fibroblasts 
In order to investigate whether metformin impacts lipogenic versus myogenic fibroblastic 
phenotypes in the lung, we carried out a dose-finding study. Human lung fibroblasts  
isolated from 7 IPF patients were starved for 24 h before being treated with 1, 5 or 10 mM 
metformin for 72 h (Fig. 6). Treatment of cells with 5 mM metformin resulted in significant 
upregulation of the lipogenic markers adipose differentiation-related protein (a.k.a. 
perilipin 2, PLIN2, 18.3 folds, Fig. 6A) and PPARg (6.6 folds, Fig. 6B) in parallel to a 
significant 9.7-fold downregulation of COL1A1 (Fig. S1C). Treatment with 10 mM 
metformin led to comparable results (Fig. 6A-C). No induction of apoptosis (Fig. 6D) or 
massive cell death were observed in response to metformin treatment (5 mM). Therefore, 
we decided to use the 5 mM concentration for the rest of the study. 
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Figure 6. Dose-finding study for treating human IPF lung fibroblasts with 
metformin.  
(A-C) qPCR analysis of PLIN2, PPARg and COL1A1 in IPF fibroblasts treated with 1 
mM, 5 mM or 10 mM metformin or vehicle. (D) Western blot showing the expression of 
the apoptotic marker PARP1 in fibroblasts treated with vehicle or 5 mM metformin. 
Quantification of the immunoblot is shown in the right panel. Each data point 
corresponds to one patient. (A-C) n=6-7 per group, (D): n=3 per group. Kruskal-Wallis 
test was used in (A-C) and Mann-Whitney test was used in (D). 
 
In order to gain further insights into the dynamics of this process, human lung fibroblasts 
isolated from 5 IPF patients were treated with 5 mM metformin and analyzed after 48, 72 
and 96 h (Fig. 7A). Analysis at 48 h showed a significant 3.4-fold downregulation of 
COL1A1 expression (Fig. 7D) but without affecting lipogenic marker expression (Fig. 7B, 
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C) or lipid-droplet accumulation (as shown by staining with the neutral lipid dye LipidTOX) 
(Fig. 7K, L, Q). At 72 h, a significant 9.6-fold downregulation of COL1A1 (Fig. 7G) was 
accompanied by significant upregulation of PLIN2 (33.5 folds, Fig. 7E) and PPARg (12.4 
folds, Fig. 7F) and a 4.3-fold increase in lipid-droplet accumulation (Fig. 7M, N, R). The 
effect of metformin was comparable at 96 h (Fig. 7H-J, O, P, S). These data indicate that 
metformin first leads to COL1A1 downregulation and then induces lipogenic marker 
expression in primary human IPF lung fibroblasts. The 72 h time point was chosen for 
subsequent analyses. 
Following the establishment of an optimal dose and time point for metformin treatment, 
pulmonary fibroblasts isolated from 12 IPF patients were treated with 5 mM metformin 
and analyzed after 72 h (Fig. 8A). The results showed significant upregulation of PLIN2 
(22.1 folds, Fig. 8B) and PPARg (8.3 folds, Fig. 8C), and a robust 8.1-fold downregulation 
of COL1A1 (Fig. 8D). Despite the variation in the response of fibroblasts isolated from 
different patients, the pattern of response was highly significant and clearly consistent 
among all samples (i.e. induction of lipogenic marker expression and suppression of 
COL1A1 expression). As a final readout for lipogenic differentiation, the neutral lipid stain 
LipidTOX was used and the increase in lipid-droplet accumulation in fibroblasts was 
demonstrated by fluorescence microscopy (Fig. 8E, F). Flow cytometry-based 
quantification of LipidTOX+ cells displayed a significant 2.1-fold increase in metformin-
treated cells compared to vehicle-treated cells (Fig. 8G-I). 
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Figure 7. Metformin induces lipogenic differentiation in IPF fibroblasts starting at 
72 h after treatment.  
(A) Schematic representation of the experimental setup. (B-D) qPCR analysis of PLIN2, 
PPARg and COL1A1 in IPF fibroblasts treated with 5 mM metformin for 48 h. A Similar 
analysis is shown after 72 (E-G) and 96 h (H-J). (K-P) Staining of metformin- and 
vehicle-treated cells with LipidTOX (red) and DAPI (blue) at 48, 72 and 96 h. (Q-S) 
Quantification of lipid-droplet accumulation shown in (K-P). Scale bars: (K-P) 25 µm. 
Each data point corresponds to one patient. (B-J) n=4-5 per group. (Q-S) n=4 per group. 
Mann-Whitney test was used in (B-J, Q-S). 
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Figure 8. Metformin induces lipogenic marker expression in human IPF lung 
fibroblasts. (A) Schematic representation of the experimental setup. (B-D) qPCR 
analysis for the lipogenic marker genes PLIN2 and PPARg, as well as the myofibroblast 
marker COL1A1 in human IPF lung fibroblasts treated with metformin or vehicle. (E, F) 
Staining of lipid droplets in fibroblasts using LipidTOX (red). Nuclei were counterstained 
with DAPI (blue). (G-H) Gating strategy for detecting LipidTOX+ cells by flow cytometry. 
(I) Quantification of LipidTOX+ cell abundance in response to metformin treatment. (J) 
Heatmap representation of the top 100 differentially expressed genes in fibroblasts 
following metformin treatment. (K) qPCR analysis for BMP2 in metformin- and vehicle-
treated cells. Scale bars: (E, F) 25 µm. Each data point within a given group 
corresponds to one patient. (B-D) Vehicle-treated group: n=12, Metformin-treated 
group: n=11. (I) n=3 per group. (K): n=5 per group. Student’s t-test was used in (B-D) 
and Mann-Whitney test was used in (I, K). 
 
In order to explore global patterns of gene expression regulation induced by metformin 
and to generate further hypotheses, gene expression microarrays were carried out for 4 
vehicle-treated and 3 metformin-treated human IPF lung fibroblasts. A heatmap depicting 
the top 100 differentially regulated genes (based on z-values) are shown in Fig. 8J. 
Interestingly, KEGG pathway analysis revealed that metformin treatment led to the 
modulation of several metabolic pathways, few of which have previously been 
implemented in IPF such as glycosaminoglycan biosynthesis - heparan sulfate / heparin 
(P=0.003), sphingolipid metabolism(Zhao et al., 2017) (trend) and arginine/proline 
metabolism (trend) (Fig. 9). The latter pathway is relevant to collagen synthesis. In 
agreement with our observation that metformin induces lipogenic differentiation in human 
IPF lung fibroblasts, pathway analysis also showed statistically significant modulations of 
fatty acid metabolism (P=0.006), biosynthesis of unsaturated fatty acids (P=0.02), 
glycerolipid metabolism (P=0.03) and fatty acid elongation (P=0.04) (Fig. 9). Although not 
statistically significant, there were also trends for modulations of other relevant pathways 
such as linoleic acid metabolism, insulin signaling pathway, fatty acid degradation and 
fatty acid biosynthesis (Fig. 9). We also inspected selected markers of lipogenic 
differentiation to validate the microarray data and we observed upregulation of PLIN2 
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(P=0.001), PPARg (trend) and CEBPB (P=0.003) coupled to significant downregulation 
of the myofibroblast marker COL1A1 (P=0.002). Other significantly modulated metabolic 
pathways included steroid biosynthesis (P=7.9x10-5), vitamin B6 metabolism (P=0.001), 
drug metabolism – cytochrome P450 (P=0.004), terpenoid backbone biosynthesis 
(P=0.006), retinol metabolism (P=0.006), N-Glycan biosynthesis (P=0.007), glycolysis / 
gluconeogenesis (P=0.01) and metabolism of xenobiotics by cytochrome 450 (P=0.02) 
(Fig. 9). The microarray data also showed significant modulation of the TGFβ signaling 
pathway (P=0.01). Intriguingly, the top upregulated gene in metformin-treated fibroblasts 
was BMP2 (red arrow in Fig. 8J). This finding was validated by qPCR and the result 
indeed showed significant upregulation of BMP2 in metformin-treated cells compared to 
vehicle-treated controls (Fig. 8K). 
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Figure 9. KEGG significance plot showing signaling pathway alterations in 
metformin- and vehicle-treated human IPF lung fibroblasts.  
The top 75 candidate pathways are shown. Note the statistically significant modulations 
observed for metabolic pathways related to glycosaminoglycan biosynthesis – heparan 
sulfate / heparin, fatty acid metabolism, glycerolipid metabolism and fatty acid 
elongation. PPAR and TGFβ signaling pathways are also among the top candidates. 
The dashed red line represents the cut-off value of P=0.05. Vehicle-treated group: n=4, 
metformin-treated group: n=3. 
 
4.3.2. Metformin inhibits TGFβ1-mediated fibrogenesis in vitro 
The TGFβ1 signaling pathway is widely regarded as the master regulator of fibrogenesis 
in vitro and in vivo. In order to investigate whether metformin inhibits the profibrotic effect 
of TGFβ1 in vitro, primary lung fibroblasts isolated from 10 IPF patients were starved for 
24 h and then treated with 2 ng/mL rhTGFβ1 (or vehicle) for 72 h and then treated with 5 
mM metformin (or vehicle) for 72 h (Fig. 10A). This experimental setup allows examining 
the ability of metformin to change the phenotype of myofibroblasts that arise from TGFβ1 
treatment. The effect of TGFβ1 treatment was validated after 72 h by qPCR and the 
results showed significant downregulation of the lipogenic markers PLIN2 (Fig. 10B) and 
PPARg (Fig. 10C) in parallel to significant upregulation of COL1A1 (Fig. 10D) as we 
previously described(El Agha et al., 2017). We also expected that activation of TGFβ1 
signaling would result in disappearance of lipid droplets at the expense of ACTA2 and 
COL1A1 upregulation. To test this hypothesis, cells were stained with LipidTOX and anti-
ACTA2 antibodies. Fluorescent microscopy showed increased abundance of ACTA2 
filaments (Fig. 10H) and absence of lipid droplets (Fig. 2F) in TGFβ1-treated cells 
compared to vehicle-treated cells (Fig. 10E, G) after 72 h. Time-lapse microscopy of 
vehicle- (supplementary movie 1), rhTGFβ1- (supplementary movie 2) or metformin-
treated cells (supplementary movie 3) in the presence of LipidTOX was also carried out 
for 68 h. Metformin led to an increase in lipid-droplet accumulation after 48 h while vehicle 
or rhTGFβ1 treatment led to cell elongation and disappearance of lipid droplets. 
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Next, the response to metformin treatment was analyzed. At the end of day 6 (144 h), 
qPCR showed significant upregulation of PLIN2 (4.6 folds, Fig. 10I) and PPARg (1.3 folds, 
Fig. 2J), and a significant 7.1-fold downregulation of COL1A1 expression (Fig. 10K) in the 
[TGFβ1 plus metformin] group compared to the [TGFβ1 plus vehicle] group. Interestingly, 
lipid-droplet accumulation was regained in fibroblasts treated with [TGFβ1 plus 
metformin] compared to the [TGFβ1 plus vehicle] group (Fig. 10L, M). These results 
suggest that metformin affects the phenotype of myofibroblasts arising from TGFβ1 
treatment by downregulating myogenic markers and inducing lipogenic differentiation. 
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Figure 10. Metformin attenuates TGFβ1-mediated fibrogenesis in vitro.  
(A) Schematic representation of the experimental setup. (B-D) qPCR analysis for 
PLIN2, PPARg and COL1A1 in human lung fibroblasts treated with TGFβ1 or vehicle 
for 72 h. (E-H) Staining of TGFβ1- and vehicle-treated cells with LipidTOX (red), anti-
ACTA2 antibodies (green) and DAPI (blue). (I-K) qPCR analysis for PLIN2, PPARg and 
COL1A1 in human lung fibroblasts treated with TGFβ1 or vehicle for 72 h, followed by 
treatment with metformin or vehicle for 72 h. (L-M) Staining of TGFβ1- and vehicle-
treated cells with LipidTOX (red) and DAPI (blue) at the end of treatment (t=144 h). 
Scale bars: (E-H) and (L-M) 25 µm. Each data point within a given group corresponds 
to one patient. (B-D) n=4 per group. (I-K) n=9-10 per group. Mann-Whitney test was 
used in (B-D), one-way ANOVA was used in (I, J) and Kruskal-Wallis test was used in 
(K). 
 
4.3.3. Metformin improves lung structure in an ex vivo system 
 
One drawback of using cell-culture systems is that cells growing in vitro are deprived of 
their microenvironmental cues and their behavior might not resemble that of an in vivo 
context. We therefore set out to test whether metformin exerts similar beneficial effects in 
a more complex system that better mimics the in vivo setting. Therefore, we used 
precision-cut lung slices (PCLS), an ex vivo culture system which allows maintenance of 
viable, metabolically active lung tissue with preserved structure for five days. Two 
hundred micrometer-thick PCLS were prepared from fibrotic regions of fresh IPF lung 
tissues and were cultured in DMEM supplemented with 10% BCS in the presence or 
absence of 5 mM metformin for five days (Fig. 11A). Bright-field imaging showed that 
metformin-treated PCLS displayed a more relaxed structure with open airspaces (Fig. 
11E) compared to their vehicle-treated counterparts (Fig. 11D). PCLS were then 
embedded in paraffin, sectioned into 5 µm-thick slices, and processed for histological 
analysis. Hematoxylin and eosin staining (Fig. 11H, I), Masson’s trichrome staining (Fig. 
11J, K) and COL1A1 immunostaining (Fig. 11L, M) showed improved lung structure and 
decreased collagen deposition in metformin-treated samples compared to controls. 
Another set of PCLS was not sectioned but was subjected to whole-mount staining using 
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anti-COL1A1 antibodies and LipidTOX followed by confocal microscopy. Three-
dimensional (3D) reconstruction using z-stacks acquired from these samples revealed 
decreased COL1A1 expression and increased lipid-droplet accumulation (Fig. 11N, O). 
Flow cytometry-based quantification confirmed the histological observations and showed 
a significant increase in the abundance of lipid-droplet-containing cells (following 
depletion of CD45+ bone marrow-derived cells, CD31+ endothelial cells and EpCAM+ 
epithelial cells) in metformin-treated PCLS (12 ± 0.6%) compared to controls (7.2 ± 1.1%) 
(Fig. 11P, Q). Finally, total collagen assay showed a significant reduction in collagen 
content from 26.9 ± 0.9 µg/µL to 20.8 ± 0.9 µg/µL in response to metformin treatment 
(Fig. 11R). 
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Figure 11. Metformin improves IPF lung structure ex vivo. 
(A) Schematic representation of the experimental setup. (B-E) Bright-field imaging of 
PCLS treated with metformin or vehicle for five days. (F, G) Hematoxylin and eosin 
staining and COL1A1 immunostaining of PCLS prepared from a non-IPF donor lung. 
(H-M) Hematoxylin and eosin staining, Masson’s trichrome staining and COL1A1 
immunostaining of PCLS prepared from an IPF lung and treated with metformin or 
vehicle for five days. (N, O) 3D-reconstruction of z-stacks of metformin- and vehicle-
treated PCLS stained for COL1A1 (green) and lipid droplets (red). (P) Gating strategy 
for flow cytometry-based quantification of LipidTOX+ cells that are negative for 
hematopoietic (CD45), endothelial (CD31) and epithelial (EpCAM) cell markers. (Q) 
Quantification of flow cytometry measurements on metformin- and vehicle-treated cells. 
(R) Total collagen assay for metformin- and vehicle-treated cells. Scale bars: (B-E) 2 
mm, (F) 500 µm, (G, L, M) 50 µm, (H-K) 200 µm. Each data point within a given group 
corresponds to one patient. (Q) n=4 per group. (R) n=3 per group. Mann-Whitney test 
was used in (Q, R). 
 
4.3.4. Metformin accelerates resolution of bleomycin-induced pulmonary 
fibrosis in mice  
 
We next sought to test whether the ability of metformin to alter the myofibroblast fate also 
applies to the in vivo context of lung fibrosis. In order to address this question, we 
employed a lineage-tracing approach in the context of bleomycin-induced pulmonary 
fibrosis (Fig. 12). This model of injury is reversible and animals start to spontaneously 
recover from lung fibrosis after day 14. Moreover, we previously reported that the Acta2-
Cre-ERT2; tdTomatoflox lineage-tracing tool allows genetic labeling of ACTA2+ 
myofibroblasts as they accumulate during the buildup of lung fibrosis when tamoxifen is 
introduced between days 5 and 14 after bleomycin injury (El Agha et al., 2017). Therefore, 
double transgenic animals were treated with bleomycin, fed tamoxifen-containing pellets 
between days 5 and 14, treated with metformin (or vehicle) starting at day 14 after 
bleomycin instillation, and were sacrificed at day 28 (Fig. 12A, B). This experimental setup 
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allows labeling myofibroblasts that form during fibrosis formation and tracing their fate 
during resolution in the presence or absence of metformin. Already upon gross optical 
inspection, hematoxylin and eosin as well as masson’s trichrome stained lungs explanted 
at day 28 showed enhanced recovery from fibrosis upon metformin treatment (Fig. 12C-
F). Correspondingly, quantification of lung fibrosis showed a significant decrease in the 
extent of fibrosis from 12 ± 1.5% in the vehicle-treated group to 8 ± 0.6% in the metformin-
treated group (Fig. 12G). Immunofluorescent staining allowed visualization of lineage-
traced myofibroblast-derived cells (tdTomato+) and also confirmed the decrease in 
COL1A1 deposition upon metformin treatment (Fig. 12H, I). Interestingly, LipidTOX 
staining carried out on frozen sections revealed the presence of lipid droplets in 
tdTomato+ cells at day 28 (Fig. 12J, K). In order to quantify the impact of metformin on 
altering the myofibroblast fate, flow cytometry was carried out. The results showed similar 
proportions of tdTomato+ cells in both groups (Fig. 12Q), while the proportion of 
LipidTOX+ mesenchymal cells increased from 13.5 ± 2.5% to 18.8 ± 1.8% upon metformin 
treatment (Fig. 12S). More importantly, the proportion of myofibroblast descendants 
(tdTomato+) that also contained lipid droplets increased from 6.8 ± 0.1% in the control 
group to 12.2 ± 0.5% in the metformin-treated group (Fig. 12R). Collectively, these data 
clearly demonstrate that metformin accelerates fibrosis resolution and this is 
accompanied by the induction of myogenic-to-lipogenic conversion in lung fibroblasts in 
vivo. 
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Figure 12. Metformin accelerates fibrosis resolution in the bleomycin model in 
mice.  
(A) Schematic representation of the Acta2-Cre-ERT2 and tdTomatoflox construct. (B) 
Schematic representation of the timeline of the experiment. Bleomycin was 
administered intratracheally at day 0. Between days 5 and 14, mice were fed tamoxifen-
containing pellets and starting at day 14, metformin (1.5 mg/mL) or vehicle was 
administered through drinking water. Mice were sacrificed at day 28. (C-F) Hematoxylin 
and eosin and Masson’s trichrome staining of metformin- and vehicle-treated lungs. (G) 
Quantification of fibrosis in metformin- and vehicle-treated lungs. (H, I) 
Immunofluorescence for COL1A1 (green). Endogenous tdTomato signal (red) and 
DAPI (blue) are also shown. (J) LipidTOX staining (green) and tdTomato+ cells (red) 
are shown. The box in (J) is magnified in (K). Arrowheads indicate LipidTOX+ 
tdTomato+ cells. (L-S) Gating strategy (to detect CD45- CD31- EpCAM- tdTomato+ 
and/or LipidTOX+ cells) and quantification of various cell populations based on 
tdTomato and LipidTOX detection. Scale bars: (C-F) 1 mm, (H, I) 50 µm, (J) 25 µm. 
Each data point within a given group corresponds to one animal. n=5 per group. Mann-
Whitney test was used in (G, Q-S). 
 
4.3.5. The mechanism of action of metformin in human lung fibroblasts is 
only partially dependent on AMPK signaling 
 
Activation of the AMPK signaling cascade is one of the major molecular mechanisms that 
have been proposed for metformin. In order to investigate whether metformin-mediated 
lipogenic differentiation is AMPK-dependent, gain and loss-of-function approaches were 
carried out. In a first set of experiments, primary human lung fibroblasts isolated from 8 
IPF patients were cultured and treated with GSK621 (a selective activator of AMPK 
signaling pathway) for 72 h (Fig. 13A). The results showed a trend for mild downregulation 
of the lipogenic markers PLIN2 (Fig. 13B) and PPARg (Fig. 13C) in parallel to a robust, 
significant downregulation of COL1A1 (Fig. 13D). Accordingly, GSK621 treatment failed 
to promote lipid-droplet accumulation in these cells (Fig. 13L-N). 
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In another set of experiments, primary human lung fibroblasts isolated from 5 IPF patients 
were transfected with siRNAs targeting AMPK. After 72 h, cells were treated with 
metformin and were analyzed after 72 h (Fig. 13F). Western blotting revealed a 90% 
knockdown of AMPK in these cells compared to scramble-transfected cells at the time of 
analysis (Fig. 13J, K). Interestingly, metformin treatment led to upregulation of PLIN2 and 
PPARg regardless of AMPK knockdown (Fig. 13G, H). Metformin-mediated COL1A1 
downregulation, however, was attenuated upon AMPK knockdown (Fig. 13I). Altogether, 
these data demonstrate that the mechanism of action of metformin in promoting lipogenic 
differentiation in human lung fibroblasts is largely independent of AMPK signaling while 
inhibition of COL1A1 production is mainly AMPK-dependent. 
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Figure 13. Mode of action of metformin is partially independent of AMPK 
signaling. 
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(A) Schematic representation of the gain-of-function experimental setup for AMPK 
signaling. (B-E) qPCR analysis of PLIN2, PPARg, COL1A1 and BMP2 in human IPF 
lung fibroblasts treated with the AMPK agonist GSK621 or vehicle. (F) Schematic 
representation of the loss-of-function experimental setup for AMPK signaling. (G-I) 
qPCR analysis of PLIN2, PPARg and COL1A1 in IPF fibroblasts treated with AMPK 
siRNA or scramble siRNA. The decrease of AMPK protein levels at the time of analysis 
is shown in (J, K). (L-N) Staining of GSK621- and vehicle-treated cells with LipidTOX 
(red) and DAPI (blue). Metformin-treated cells were used as a positive control for lipid-
droplet accumulation (M). Scale bars: (L-N) 25 µm. Each data point corresponds to one 
patient. (B-E) Vehicle-treated group: n=8, GSK621-treated group: n=8. (G-I) n=4 per 
group. (K) n=3 per group. Mann-Whitney test was used in (B-E, K) and Kruskal-Wallis 
test was used in (G-I). 
 
4.3.6. Metformin induces the expression of lipogenic markers via induction 
of BMP2 expression and phosphorylation of PPARγ 
 The next step was to better define the molecular mechanism by which metformin induces 
lipogenic differentiation in human lung fibroblasts. Our gene expression microarrays 
showed that BMP2 was the top upregulated gene in fibroblasts upon metformin treatment 
(Fig. 8J). BMP2 is known to inhibit smooth muscle cell growth in a mechanism involving 
PPARγ activation. Calvier et al. also reported that BMP2 inhibits TGFβ1 signaling via 
PPARγ in vascular smooth muscle cells in the lung(Calvier et al., 2017). Therefore, we 
treated 11 human IPF lung fibroblasts with rhBMP2 and gene expression was analyzed 
after 72 h (Fig. 14A). Intriguingly, rhBMP2 treatment resulted in significant upregulation 
of PLIN2 (1.9 folds, Fig. 14B) and PPARg (2.5 folds, Fig. 14C), while COL1A1 expression 
levels remained unchanged (Fig. 14D). LipidTOX staining confirmed the increase in lipid-
droplet accumulation in these cells (Fig. 14E, F). We then performed siRNA-mediated 
knockdown of PPARg in human IPF lung fibroblasts (Fig. 14G) and tested the effect of 
rhBMP2 treatment on lipogenic differentiation. The results showed that PPARg 
knockdown abolished rhBMP2-induced lipogenic differentiation in these cells (Fig. 14H, 
I). As expected, COL1A1 levels were not modulated by this intervention (Fig. 14J). Thus, 
BMP2 is a positive regulator of lipogenic differentiation in human IPF lung fibroblasts. The 
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activation of PPARγ signaling pathway can also be induced post-translationally via 
PPARγ phosphorylation at serine residue 112 (Ser112)(Compe et al., 2005; Iankova et al., 
2006; Zhang et al., 1996a). Therefore, we set out to determine whether BMP2 (and 
metformin) induce lipogenic differentiation in human lung fibroblasts by inducing PPARγ 
phosphorylation. Cells were treated with rhBMP2 (or vehicle) and protein lysates were 
collected after 72 h. PPARγ phosphorylation was induced 7.6 folds in rhBMP2-treated 
fibroblasts while PPARγ protein levels remained unchanged (Fig. 14K). 
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Figure 14. rhBMP2 induces PPARγ phosphorylation and lipogenic differentiation 
in human IPF lung fibroblasts. 
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(A) Schematic representation of the experimental setup. (B-D) qPCR analysis of PLIN2, 
PPARg and COL1A1 in IPF fibroblasts treated with rhBMP2 or vehicle. (E, F) Staining 
of rhBMP2- and vehicle-treated cells with LipidTOX (red) and DAPI (blue). (G) Western 
blot validating the knockdown of PPARγ levels 72 h after siRNA treatment. 
Quantification of the immunoblot is shown in the right panel. (H-J) qPCR analysis of 
PLIN2, PPARg and COL1A1 in IPF fibroblasts transfected with siRNA against PPARg 
(for 72 h) and then treated with vehicle or rhBMP2 for 72 h. (K) Western blot showing 
the induction of PPARγ phosphorylation in response to rhBMP2 treatment. Lanes 1-4 
and lanes 5-8 were run in parallel on different gels under the same conditions. 
Quantification of the immunoblot is shown in the right panel. Scale bars: (E-F) 50 µm. 
Each data point corresponds to one patient. (B-D) n=11 per group except for COL1A1 
vehicle-treated group (n=10). (G) n=4 per group. (K) Scramble/vehicle-, 
scramble/rhBMP2- and siRNA/rhBMP2-treated groups: n=5 per group, siRNA/vehicle-
treated group: n= 4. Mann-Whitney test was used in (B, D, G, K) and Student’s t-test 
was used in (C). Kruskal-Wallis test was used in (H-J). 
 
 
In another set of experiments, treatment of cells with TGFβ1 led to a 24.4-fold reduction 
in p-PPARγ levels (Fig. 7A, lanes 4-6 and Fig. 15B) while treatment with metformin led to 
a 3.3-fold increase in p-PPARγ levels (Fig. 7A, lanes 7-9 and Fig. 15B) compared to 
vehicle-treated cells (Fig. 15A, lanes 1-3 and Fig. 15B). In order to investigate whether 
metformin counteracts the profibrotic effects of TGFβ1 in fibroblasts by modulating the 
phosphorylation status of PPARγ, cells were first starved for 24 h and then treated with 
rhTGFβ1 for 72 h, followed by vehicle, rhTGFβ1 or metformin treatment for another 72 h. 
The results showed that in comparison to transient (Fig. 15A, lanes 10-12) or continuous 
treatment with rhTGFβ1 (Fig. 15A, lanes 13-15), treatment with metformin after rhTGFβ1 
treatment rescued p-PPARγ levels (Fig. 15A, lanes 16-18 and Fig. 15C). Of note, qPCR 
analysis revealed that activation of AMPK signaling via GSK621 treatment did not induce 
BMP2 expression in IPF fibroblasts (Fig. 15E), indicating that the metformin-BMP2-p-
PPARγ axis is independent of AMPK signaling. 
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In order to demonstrate that metformin-induced lipogenic differentiation is mediated by 
BMP2 signaling, cells were treated with metformin in the presence or absence of the BMP 
inhibitor noggin. The levels of p-SMAD1/5/8 were used as readout for BMP2 signaling. 
Treatment with metformin led to significant phosphorylation of SMAD1/5/8 (Fig. 15D, 
lanes 11-14 and Fig. 15E), indicating that metformin treatment indeed activates BMP2 
signaling. As expected, treatment with vehicle (Fig. 15D, lanes 1-3 and Fig. 15E), noggin 
(Fig. 15D, lanes 4-6 and Fig. 15E) or metformin + noggin (Fig. 15D, lanes 7-10 and Fig. 
15E) did not yield significant SMAD1/5/8 phosphorylation. In line with these data, qPCR 
analysis revealed that noggin treatment abolished metformin-mediated upregulation of 
PLIN2 (Fig. 15F) and PPARg (Fig. 15G) without affecting metformin-mediated 
downregulation of COL1A1 (Fig. 15H). These results indicate that metformin-induced 
lipogenic differentiation, but not collagen reduction, is mediated by BMP2 signaling.  
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Figure 15. Metformin-mediated lipogenic differentiation in human IPF lung 
fibroblasts is mediated by BMP2 signaling.  
(A-C) Western blot showing the opposing effects of metformin and rhTGFβ1 on PPARγ 
phosphorylation, and the ability of metformin to partially restore PPARγ phosphorylation 
in rhTGFβ1-treated IPF fibroblasts. Lanes 1-12 and lanes 13-18 were run in parallel on 
different gels under the same conditions. (D) Western blot showing the phosphorylation 
status of SMAD1/5/8 in the presence of metformin and/or the BMP signaling inhibitor 
noggin. Quantification of the immunoblot is shown in (E). (F-H) qPCR analysis of PLIN2, 
PPARg and COL1A1 in IPF fibroblasts treated with vehicle, metformin, noggin and 
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noggin+metformin. Each data point corresponds to one patient. (A-C) n=3 per group. 
(D) Vehicle- and noggin-treated groups: n=3 per group, metformin- and 
metformin/noggin-treated groups: n=4. (F) n=4 per group. (G) n=4 per group except for 
Nog+Metformin (n=5). (H) n=4 per group. Kruskal-Wallis test was used in (B, C, E-H). 
 
4.3.7. Pirfenidone and nintedanib do not induce lipogenic differentiation in 
human lung fibroblasts 
Currently, there are two FDA-approved drugs for treating IPF; pirfenidone, which is 
believed to act as a TGFβ1 inhibitor, and nintedanib, which is a multi-receptor tyrosine 
kinase inhibitor. Therefore, we set out to determine whether these two drugs alter lung 
fibroblast fate in a similar fashion to metformin. Firstly, primary human lung fibroblasts 
were treated with either nintedanib (1 µM) or pirfenidone (0.3 mg/ml) for 72 h (Fig. 16A). 
Quantitative real-time PCR analysis showed that neither nintedanib nor pirfenidone 
enhanced the expression of the lipogenic markers PLIN2 and PPARg (Fig. 16B, C, E, F). 
Nintedanib and pirfenidone did, however, lead to a 1.9- and 2.3-fold downregulation of 
COL1A1, respectively (Fig. 16D, G). In line with these data, LipidTOX staining did not 
reveal any change in lipid-droplet accumulation following nintedanib or pirfenidone 
treatment (Fig. 16H-J). Finally, whole-mount staining followed by confocal imaging and 
3D reconstruction of IPF-derived PCLS (cultured for five days in the presence or absence 
of nintedanib or pirfenidone) revealed a slight decrease in COL1A1 deposition without an 
evident change in the abundance of LipidTOX+ cells (Fig. 16K-O). 
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Figure 16. Nintedanib and pirfenidone do not induce lipogenic differentiation in 
IPF lung fibroblasts.  
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(A) Schematic representation of the experimental setup. (B-D) qPCR analysis of PLIN2, 
PPARg and COL1A1 in human IPF lung fibroblasts treated with nintedanib. A similar 
analysis for pirfenidone-treated cells is shown in (E-G). (H-J) Staining of nintedanib-, 
pirfenidone- and vehicle-treated cells with LipidTOX (red) and DAPI (blue). (K) 
Schematic representation of the experimental setup using PCLS. (L-N) 3D-
reconstruction of z-stacks of nintedanib-, pirfenidone- and vehicle-treated PCLS 
stained for COL1A1 (green) and lipid droplets (red). (O) Quantification of LipidTOX+ 
cells as determined by manual counting across z-stacks. Scale bars: (H-J) 50 µm. (B-
G) Each data point within a given group corresponds to one patient. (B-D) Vehicle-
treated group: n=5, nintedanib-treated group: n=6. (E-G) n=4 per group. (O) Each data 
point within a given group corresponds to one z-stack. Vehicle-treated group: n=7, 
nintedanib-treated group: n=6, pirfenidone-treated group: n=8. Mann-Whitney test was 
used in (B-G) and Kruskal-Wallis test was used in (O). 
 
In an attempt to explore modulations in serine/threonine protein kinase activities upon 
metformin treatment, human IPF lung fibroblasts were subjected to a protein kinase 
activity assay (PamStation). The results showed significantly reduced kinase activities for 
CDK1, CDK3, MAPK11/14 and ERK1/2 (Fig. 17A). Given the relevance of ERK1/2 in lung 
fibrosis(Madala et al., 2012) and the fact that PPARγ can serve as a substrate for 
MAPK(Hosooka et al., 2008; Zhang et al., 1996a), the effect of metformin in inhibiting the 
activity of ERK1/2 was validated by Western blotting and the results showed robust 
inhibition of p-ERK1/2 levels in IPF lung fibroblasts in response to metformin treatment 
(Fig. 17B). Treatment of human IPF lung fibroblasts with Selumetinib (a potent and 
selective inhibitor of MEK that is directly upstream of ERK) did not yield significant 
changes in the expression levels of lipogenic or myogenic marker genes (Fig. 17C-F). 
Therefore, we conclude that the ERK pathway is not involved in metformin-mediated myo- 
to lipofibroblast transdifferentiation and collagen reduction. 
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Figure 17. Inhibition of ERK phosphorylation does not mediate the antifibrotic 
effect of metformin in human IPF lung fibroblasts. 
 (A) Kinase activity assay as determined by PamStation analysis. (B) Western blot 
showing decreased p-ERK levels in response to metformin treatment. Quantification of 
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p-ERK levels is shown in the lower panel. (C) Schematic representation of the 
experimental setup. (D-F) qPCR analysis of PLIN2, PPARg and COL1A1 in IPF 
fibroblasts treated with selumetinib or vehicle for 72 h. Each data point corresponds to 
one patient. (B) n=6 per group. (D-F) Vehicle-treated group: n=5, Selumetinib-treated 
group: n=6. Mann-Whitney test was used 
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5. Discussion  
5.1. Formation of the lipofibroblasts during development 
Despite being described in 1970, lipofibroblasts remained one of the least studied cell 
populations in the lung until recently. During this study, we have attempted to better 
characterize these cells. Using flow cytometry, the data showed that lipofibroblast start to 
appear at late pseudoglandular stage which coincides with the start of the differentiation 
process of AECIIs (Beers and Moodley, 2017). Due to being located in close proximity of 
AECII, lipofibroblasts are believed to assist these cells in the process of surfactant 
production via shuttling of stored lipids to AECIIs (Tordet et al., 1981).  
The signaling pathways which are important for the formation of lipofibroblasts remain ill 
understood as well. Previously, our group provided evidence that a subpopulation of 
Fgf10+ mesenchymal cells gives rise to lipofibroblasts (El Agha et al., 2014). Furthermore, 
induction of Fgf10 expression in the lipofibroblasts can be one of the major sources of 
this growth factor which is crucial for the expansion and differentiation of epithelial cells 
(Ramasamy et al., 2007; Yuan et al., 2018). In addition to paracrine function, our data 
also suggests an autocrine function of Fgf10 on lipofibroblasts as well which it seems 
mainly conducted through Fgfr2b. Fgfr1b knockdown animals manifested a slight 
increase in the expression of lipofibroblastic markers and also Plin2 immunostaining 
which is most likely due to compensatory role of Fgfr2b.  
In the early developing mouse lung, it is well accepted that mesenchymal Fgf10 acts on 
the epithelium through its receptor Fgfr2b, whereas a direct action on the mesenchyme 
does not occur until E14.5 (De Langhe et al., 2006). Our results suggest that during late 
lung development, Fgf10 signals to the mesenchyme through both Fgfr2b and Fgfr1b and 
that the two receptors play redundant roles in terms of LIF formation. The expression of 
Fgfr2b in the lung mesenchyme is a novel finding that suggests a mechanism of 
alternative splicing to allow the expression of this receptor. In the future, it will be 
interesting to investigate what controls Fgfr2b expression in the mesenchyme. The 
generation of double conditional knockout of Fgfr1b/2b in the mesenchyme will also be 
important to clarify whether these two receptors are the only mediators of Fgf10 signaling 
in the lung mesenchyme. 
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5.2. Contribution of preexisting lipofibroblasts to the pool of 
activated myofibroblasts during progression of fibrosis 
The next question in the line was whether preexisting lipofibroblasts play a role in the 
progression of fibrosis. Our lineage tracing data using AdrpCre-ERT2; mT/mG mice 
showed that lipofibroblasts transdifferentiate to activated myofibroblasts at the peak of 
fibrosis (14 d.p.i.). Following observing this phenomenon another question rose whether 
pre-existing lipofibroblasts that transdifferentiate to activated myofibroblasts during 
fibrosis formation are the same cells that revert to a lipofibroblast-like phenotype following 
fibrosis resolution. Other possibility would be that the latter event is a general 
phenomenon of activated myofibroblast dedifferentiation after recovery. Unfortunately, 
due to the patchy and heterogeneous pattern of lung fibrosis, it cannot be concluded with 
certainty that either of these two scenarios is true.  
PPARg, the main conductor of lipogenic differentiation in preadipocytes as well as 
mesenchymal stem cells, is also involved in lipofibroblast formation (Rehan and Torday, 
2012) and PPARg agonists have been shown to protect mice from developing fibrosis 
(Fang et al., 2012; Genovese et al., 2005). Furthermore, adiponectin, which is a direct 
transcriptional target for PPARg, has shown a similar effect in primary culture of skin 
fibroblasts isolated from scleroderma patients (Fang et al., 2012). Here, we show that 
PPARg signaling is inhibited in IPF, likely due to hyperactive TGFb1 signaling. We also 
provide further mechanistic insights into the mode of action of rosiglitazone. We show 
that TGFb1 represses the lipogenic program by inhibiting PPARg expression in favor of 
the activation of the myogenic program in primary human lung fibroblasts. Conversely, 
rosiglitazone reinforces the lipogenic phenotype and inhibits TGFb1-mediated 
fibrogenesis. Thus, it is likely that in IPF, endogenous PPARg signaling is unable to 
counteract TGFb1 signaling without an exogenous stimulus. Our data emphasize the 
phenotypic 
 A recent study has reported the absence of lipid-droplet-containing cells in the human 
lung (Tahedl et al., 2014), although a previous study clearly demonstrated the presence 
of Oil Red O+ cells in both infant and adult human lungs (Rehan et al., 2006). In this 
study, we used the neutral lipid fluorescent stain LipidTOX and we clearly demonstrate 
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the presence of resident lipogenic cells that are located adjacent to AEC2 in human lungs. 
The discrepancy between the aforementioned findings might be related to the 
unsaturated fatty acid composition of lipid droplets in the human lung and the differences 
in detection methods (Ahlbrecht and McGowan, 2014). The process of spontaneous 
myofibroblast dedifferentiation observed in the mouse model of lung fibrosis is yet to be 
investigated in human IPF lungs. However, the data attained with human lung fibroblasts 
indicate that this process can be induced through intervention with PPARg agonists. 
Whether myofibroblasts are able to dedifferentiate to cell types other than lipofibroblasts 
is yet to be established. To date, there is a gap in the knowledge regarding cellular 
heterogeneity of human lung mesenchyme, apart from the classification of lung fibroblasts 
into lipogenic and myogenic populations. Thus, there is an urgent need to employ 
emerging new technologies such as single-cell RNA-seq to assess mesenchymal 
heterogeneity in the human lung and identify new cell types based on unique surface 
markers and molecular signatures. Such an approach might uncover novel fibroblastic 
populations and open new avenues to cure, or at least attenuate, IPF. 
5.3. Metformin enforces lipogenic phenotype in activated 
myofibroblasts and accelerates resolution of fibrosis 
There is emerging literature about the association between metabolic disorders and IPF 
incidence. Our group and others have already shown that the PPARγ agonist 
rosiglitazone, which is an antidiabetic agent, counteracts TGFβ1-mediated fibrogenesis 
in vitro and in vivo (El Agha et al., 2017; Burgess et al., 2005; Genovese et al., 2005). In 
this study, we demonstrate that the first-line antidiabetic drug, metformin, inhibits collagen 
production in primary human lung fibroblasts and in ex vivo cultured human IPF PCLS 
and strongly enhances myo- to lipofibroblast transdifferentiation linked with phenotypic 
recovery from fibrosis (Fig.18). 
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Figure 18. Model for the antifibrotic mechanism of action of metformin in 
human lung fibrosis.  
Metformin activates AMPK signaling in myofibroblasts, leading to suppression of 
collagen production, and induces lipogenic differentiation via an AMPK-independent 
mechanism involving BMP2 release and PPARγ phosphorylation. Arising 
lipofibroblasts are known to support type 2 alveolar epithelial stem cells in the lung. 
 
 Although the PCLS culture system does not fully recapitulate the in vivo situation, it adds 
cellular, molecular and matrix complexity compared to standard cell culture techniques 
and – in our opinion – offers a valuable preclinical analytical tool. Accordingly, therapeutic 
application of metformin in bleomycin-injured mice resulted in accelerated resolution of 
fibrosis by altering the fate of fibrosis-associated myofibroblasts and inducing their 
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lipogenic differentiation. In our in vivo experiments, metformin was introduced through 
drinking water and the effects on lung repair were evident based on fibrosis assessment 
and myofibroblast fate switching. No adverse, systemic side effects of such treatment 
were observed. Although metformin is safe and well tolerated in humans, it confers the 
risk of hypoglycemia in case of long-term use, although this risk is still lower than that 
associated with other antidiabetic agents (Leonard et al., 2018). Notably, detailed 
pathway analysis showed that the reduction of collagen synthesis was largely AMPK-
dependent, whereas the transdifferentiation of myo- to lipofibroblasts occurred in a BMP2-
PPARγ-dependent fashion and was largely AMPK-independent. 
As mentioned above PPARγ is the master regulator of adipogenesis and it is expressed in 
various cell types in the human body. Its functions include – in addition to differentiation 
and maintenance of adipocytes (Siersbaek et al., 2010) - regulation of inflammatory 
responses in macrophages (Malur et al., 2009), regulation of osteogenesis (Sun et al., 
2013) and cell metabolism (Lodhi and Semenkovich, 2014). Therefore, its role in 
homeostasis and disease is strictly context-dependent. PPARγ phosphorylation has been 
shown to act as an activation or inhibitory signal depending on the protein kinase involved 
and the cell type being studied. For example, an earlier study has shown that 
phosphorylation of Ser112 in the N-terminal transactivation domain of PPARγ by MAPK 
acts as an activation signal in Chinese hamster ovary (CHO) cells (Zhang et al., 1996a). 
On the other hand, a later study has shown that the same phosphorylation event of 
PPARγ by MAPK is an inhibitory signal in white adipose tissue (WAT) (Hosooka et al., 
2008). Moreover, phosphorylation of the same serine residue in WAT by cyclin-dependent 
kinase 7 (CDK7) acts as an activation signal (Compe et al., 2005), and so does 
phosphorylation by CDK9 in the embryonic mouse preadipocyte cell line 3T3-L1 (Iankova 
et al., 2006). Therefore, it is clear that the outcome of phosphorylation in terms of PPARγ 
activation and consequently lipogenic differentiation is context-dependent. In this study, 
we found that metformin significantly upregulates BMP2 and PPARg (at the mRNA level), 
increases the phosphorylation of PPARγ protein at Ser112, upregulates the downstream 
target PLIN2 (Rehan and Torday, 2012; Varisco et al., 2012) and induces lipid-droplet 
acumulation in human IPF lung fibroblasts. Interestingly, it has been reported that 
metformin inhibits the upregulation of PPARg and PLIN2 in mouse hepatocytes in 
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response to fructose diet (Karise et al., 2017). Metformin, however, does not alter PPARg 
and PLIN2 expression levels in animals that receive normal diet (Karise et al., 2017). 
Moreover, it has been shown that metformin inhibits adipogenesis in mesenchymal stem 
cells (Chen et al., 2017) and 3T3-L1 preadipocytes (Alexandre et al., 2008). Therefore, 
the biological and physiological outcome of metformin treatment is clearly context-and 
cell type-specific. 
In an attempt to explore modulations in serine/threonine protein kinase activities upon 
metformin treatment, human IPF lung fibroblasts were subjected to a protein kinase 
activity assay (PamStation). The results showed significantly reduced kinase activities for 
CDK1, CDK3, MAPK11/14 and ERK1/2. It is worth mentioning that CDK7 and CDK9 did 
not show a conclusive activity profile (data not shown). Considering the relevance of 
ERK1/2 in lung fibrosis (Madala et al., 2012) and the fact that PPARγ can serve as a 
substrate for MAPK (Hosooka et al., 2008; Zhang et al., 1996a), we validated the effect 
of metformin in inhibiting the activity of ERK1/2 by Western blotting and the results 
showed robust inhibition of p-ERK1/2 levels in IPF lung fibroblasts in response to 
metformin treatment. Treatment of human IPF lung fibroblasts with Selumetinib (a potent 
and selective inhibitor of MEK that is directly upstream of ERK) did not yield significant 
changes in the expression levels of lipogenic or myogenic marker genes (Fig. S5C-F). 
Therefore, we conclude that the ERK pathway is not involved in metformin-mediated myo- 
to lipofibroblast transdifferentiation and collagen reduction. Our finding that loss of 
function of AMPK did not affect lipogenic differentiation in response to metformin 
treatment suggests that AMPK is not the major kinase responsible for PPARγ 
phosphorylation and lipogenic differentiation. The identity of the protein kinase(s) 
responsible for PPARγ phosphorylation at Ser112, including members of the CDK family, 
and induction of lipogenic differentiation in response to metformin or BMP2 treatment 
warrants further investigations. Recently, two independent groups have shown that 
metformin inhibits the profibrotic effect of TGFβ1 in lung fibroblasts via AMKP activation 
(Rangarajan et al., 2018; Sato et al., 2016b). Our data are in line with these reports, but 
additionally reveal a novel mechanism by which metformin acts on lung fibroblasts to 
attenuate fibrosis. We show a central role for BMP2-PPARγ-induced myofibroblast-to-
lipofibroblast transdifferentiation in the process of fibrosis resolution in response to 
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metformin. Our gain-of-function experiments showed that while AMPK activation 
significantly downregulated COL1A1, it did not induce BMP2 and lipogenic marker 
expression or lipid-droplet accumulation, which indicates that activation of the AMPK 
pathway alone is not enough to trigger the transdifferentiation of myofibroblasts into 
lipofibroblasts. Correspondingly, knockdown of AMPK did not abolish metformin-
mediated induction of lipogenic markers but attenuated the suppression of COL1A1 
expression. These data suggest that alternative signaling mechanisms also contribute to 
the antifibrotic effects of metformin. Our data strongly suggest that BMP2 upregulation 
and PPARγ phosphorylation are centrally involved in these mechanisms. Interestingly, 
although treatment of primary human IPF lung fibroblasts with rhBMP2 was sufficient to 
phosphorylate PPARγ and induce lipogenic marker expression, rhBMP2 treatment did 
not result in COL1A1 downregulation. Additionally, inhibition of BMP2 signaling 
suppressed metformin-induced lipogenic differentiation without affecting the ability of 
metformin to inhibit collagen production, and knockdown of PPARg abolished the ability 
of BMP2 to induce lipogenic differentiation. Therefore, we propose a model in which 
metformin firstly activates AMPK signaling, which downregulates COL1A1, and secondly 
activates an alternative pathway involving BMP2 upregulation and PPARγ 
phosphorylation, which induces lipogenic differentiation. 
Myofibroblast-to-lipofibroblast trans- or redifferentiation is a central hitherto largely 
underappreciated route for resolution of lung fibrosis. Side-by-side comparison of 
metformin with pirfenidone and nintedanib showed that the latter agents did not converge 
on this resolution route. It is worth mentioning that cells and tissues used for pirfenidone, 
nintedanib or metformin treatment were derived from the same patients. Metformin, like 
rosiglitazone and maybe other antidiabetic medications, may add a unique antifibrotic 
profile by inducing transdifferentiation of myo- to lipofibroblasts. Another likely possibility 
is that since IPF lung tissues are derived from end-stage patients that underwent lung 
transplantation, it might be that these samples had developed resistance to pirfenidone 
and nintedanib. Nevertheless, the robust response of these samples to metformin 
treatment in terms of COL1A1 downregulation and lipogenic differentiation highlights the 
therapeutic potential of metformin in IPF.  
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Many reports have described the involvement of metformin in manipulating various 
metabolic pathways (Gonzalez-Barroso et al., 2012; Phielix et al., 2011; Viollet et al., 
2012). In fact, metformin is known to disrupt mitochondrial complex I, thus inhibiting 
cellular respiration. Recently, Zhao et al. published an extensive analysis of metabolic 
alterations in IPF lungs compared to donors (Zhao et al., 2017). They concluded that 
several types of long- and medium-chain fatty acids are enriched in IPF lungs (Zhao et 
al., 2017). Sphingolipid metabolism was found to be suppressed while arginine 
metabolism was found to be enhanced in the IPF lungs (Zhao et al., 2017) Our KEGG 
analysis on metformin-treated human lung fibroblasts suggests that metformin might be 
able to correct such metabolic dysregulations. Better understanding of the metabolic 
switch in lung fibroblasts in response to metformin and the mechanisms leading to 
accumulation of lipid droplets warrants further research. Additionally, we cannot exclude 
that the beneficial effect of metformin in the context of lung fibrosis could also be attributed 
to direct effects on AT2, rather than solely mediated by effects on mesenchymal cells. In 
the future, it would be extremely important to establish a mesenchyme-free AT2 culture 
model (derived from IPF lungs) and test the effect of metformin, as well as other 
therapeutic candidates, in this context. Last but not least, the therapeutic role of metformin 
described in this study might also apply to other fibrotic diseases such as liver fibrosis 
and scleroderma, characterized by an imbalance between myofibroblasts and adipocyte-
like cells (hepatic stellate cells) (Mederacke et al., 2013) and subcutaneous adipocytes 
(Marangoni et al., 2015; Plikus et al., 2017), respectively. 
In a recent report, post-hoc analysis was performed on IPF patients derived from the 
placebo arms of three phase 3, double-blind, controlled trials of pirfenidone(Spagnolo et 
al., 2018). In that study, 71 metformin users did not present improvements in clinical 
outcomes compared to 553 non-metformin users (Spagnolo et al., 2018). As pointed out 
by Tzouvelekis and colleagues, these data cannot be generalized into the global IPF 
population due to many caveats in the study design including the post-hoc nature of the 
study, the low number of metformin users, lack of stringent criteria for diagnosis and 
assessment of diabetes control, inability to link metformin mechanisms to IPF 
pathogenesis or to delineate drug-drug interactions (Tzouvelekis et al., 2018). Given its 
low cost and the fact that it is well tolerated in humans, it will be useful to test the curative 
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effect of metformin, either alone or in combination with other antifibrotic agents, in non-
diabetic IPF patients. A key aspect will be to identify biomarkers that predict drug 
responsiveness in the heterogeneous population of IPF patients. Given the high financial 
burden of developing novel medicines, drug repositioning might help accelerate the 
process of discovering a cure for IPF patients. 
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6. Conclusion  
This study provides a better characterization of lipofibroblasts during lung development 
and their contribution to progression of pulmonary fibrosis. Furthermore, it gives more 
insight regarding potential therapeutic efficacy of the first line antidiabetic drug, metformin, 
in reversing pulmonary fibrosis via enforcing lipogenic phenotype in activated 
myofibroblasts.  
In the first part of this study, dynamics of lipofibroblast formation and involvement of 
FGF10 signaling in this procedure were explored. Lipofibroblasts start to appear at late 
pseudoglandular stage in the lung development.  
Next, the hypothesis that whether lipofibroblasts can contribute to the pool of activated 
myofibroblasts and revert back to their original status were examined. Lineage tracing 
experiments, showed that preexisting lipofibroblasts indeed transdifferentiate to activated 
myofibroblasts due to hyperactive TGFβ1 signaling and revert to their lipogenic form 
during resolution phase. Suppression of PPARg signaling pathway, as the master switch 
of lipogenesis, via TGFβ1 can be rescued by forced activation of this signaling pathway 
using PPARg agonists such as rosiglitazone.   
Later, the potential therapeutic effect of metformin on reversing pulmonary fibrosis was 
investigated. The data revealed that metformin can effectively attenuate TGFβ1 induced 
trans-differentiation to activated myofibroblasts and enforce activation of lipogenic 
pathways in the fibroblasts. In addition to primary culture of fibroblasts, this phenomenon 
was confirmed in ex-vivo model of lung organ culture, also known as Precision Cut Lung 
Slices (PCLS) and in-vivo model of bleomycin induced fibrosis. Furthermore, data 
demonstrated activation of a novel BMP2-PPARg axis following metformin treatment. 
Metformin induces production of BMP2 which in a potentially auto and paracrine manner 
results in activation of BMP2 signaling. This results in increasing level of PPARg 
phosphorylation which results in lipogenic differentiation. 
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7. Summary 
As of today, lipofibroblasts remain as one of the most ill-defined cell populations is the 
lung. They are part of the lung mesenchyme and contain lipid droplets. Since they are 
located near alveolar epithelial type II cells, they shuttle the accumulated lipid droplets 
into AECII cells and support them with surfactant production. Our data revealed that 
lipofibroblasts start to emerge at E16.5 which is around the time that AECIIs start to 
appear. FGF10 acts in an autocrine and paracrine fashion on mesenchymal and epithelial 
cells which are crucial for the formation of LIFs and AECIIs. In the next step we have 
provided evidence regarding the contribution of lipofibroblasts to the pool of activated 
myofibroblasts during progression of fibrosis. In brief LIFs transdifferentiate to activated 
myofibroblasts due to hyperactivity of TGFβ1 signaling. Following the fate of these cells, 
our lineage tracing using AdrpCre-ERT2; tdTomatoflox mouse line, confirmed that during 
resolution phase, activated myofibroblasts, which were resulted from transdifferentiation 
of lipofibroblasts, revert back to their original status. Activation of PPARg signaling via 
treatment of cells with rosiglitazone negated the effects of TGFβ1 treatment and enforced 
the lipogenic phenotype in the pulmonary fibroblasts.  
Following this concept, we hypothesized that treatment of the fibrotic lungs with reagents 
which activate PPARg signaling and enforce lipogenic phenotype in the activated 
myofibroblasts would yield beneficial effects for the patients. However, since rosiglitazone 
might not be the best choice due to increased risk of ischemic heart failure in the patients, 
we set the journey to find other antidiabetic drugs which would manipulate the cellular 
metabolism of activated myofibroblasts in the favor of lipofibroblasts. Thus, we decided 
to investigate the potential of metformin in conducting such effects. Treatment of 
pulmonary fibroblasts with TGFβ1 (forcefully transdifferentiating them to activated 
myofibroblasts) followed by metformin resulted in efficient suppression of TGFβ1 
signaling and transdifferentiation to lipofibroblasts. To better mimic the in vivo situation, 
we cultured fresh PCLSs from human IPF patients and treated them with metformin. The 
results showed obvious improvement of tissue architecture, reduction of COL1A1 and 
increasing number of lipofibroblasts. The same readouts were also confirmed via 
treatment of bleomycin injured ACTA2-CreERT2, tdTomatoflox mice starting at 14 d.p.i. for 
the next 14 days. Metformin is a well-known agonist of AMPK. While, our data showed 
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that metformin reduces expression of COL1A1 in an AMPK-dependent manner, induction 
of lipogenic markers such as PLIN2 and PPARg via metformin treatment were 
independent of AMPK. To explore the molecular mechanism behind this event, the 
transcriptome of fibroblasts treated with metformin for 72 h was analyzed. KEGG analysis 
revealed that in addition to alteration of many of the metabolic pathways in favor of 
inducing lipid droplets, BMP2 was expressed in much higher levels compared to control 
group. Treatment of fibroblasts with BMP2 induced expression of lipogenic markers and 
accumulation of lipid droplets. However, BMP2 treatment was not enough to reduce 
expression of COL1A1. Post translational modification analysis of PPARg following BMP2 
or metformin treatment, illustrated a significant increase in PPARg phosphorylation at 
Ser-112. Hence, metformin suppresses expression of COL1A1 through activation of 
AMPK, in parallel to induction of lipogenic markers via BMP2-PPARg axis.    
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8. Zusammenfassung 
Nach dem heutigen Stand der Wissenschaft, gehören die Lipofibroblasten (LIF) zu den 
wenig untersuchten Zellpopulationen der Lunge. Sie sind ein Bestandteil des 
Mesenchyms und enthalten lipidhaltige Vesikel. Aufgrund ihrer Nähe zu den 
Alveolareptihelzellen Typ II (AECII), transferieren sie die akkumulierten lipidhaltigen 
Vesikel zu den AECII Zellen und unterstützen diese damit in der Surfactantproduktion. 
Unsere Daten zeigten, dass die terminale Differenzierung der Lipofibroblasten am 
Embryonaltag 16.5 (E16.5) stattfindet, zu dem Zeitpunkt, wo die AECII erstmals in 
Erscheinung treten. FGF10 wirkt in einer autokrinen und parakrinen Weise auf die 
mesenchymalen und epithelialen Zellen, die für die Entstehung von LIFs und AECs II 
essentiell sind. Im nächsten Schritt, haben wir Beweise dafür, dass die Lipofibroblasten 
während der Fibroseenstehung einen entscheidenden Anteil an der Population der 
aktivierten Myofibroblasten beitragen. Kurz gefasst, transdifferenzieren die LIFs aufgrund 
einer Hyperaktivität von TGFß1 Signalweg zu aktivierten Myofibroblasten. Mit Hilfe der 
AdrpCre-ERT2; tdTomatoflox  Mauslinie verfolgten wir die Veränderungen der LIFs 
während der Fibroserückbildung. Wir konnten feststellen, dass die aktivierten 
Myofibroblasten, die durch Transdifferenzierung der LIFs entstanden sind, sich wieder in 
ihren Urpsrungsstatus des LIFs zurückbildeten. Die Aktivierung des PPARg Signalweges 
durch Behandlung der Zellen mit Rosiglitazone hebt den Effekt der TGFß1 Behandlung 
auf und verstärkt den lipogenen Phänotyp der pulmonalen Fibroblasten. 
Wir verfolgten dieses Konzept und stellten die Hypothese, dass eine Behandlung der 
fibrotischen Lunge mit Reagenzien, die den PPARg Signalweg aktivieren und den 
lipogenen Phänotyp in aktivierten Myofibroblasten forcieren, zu einem positiven Effekt für 
die Patienten führen könnten. Da Rosiglitazone jedoch ein erhöhtes Risiko für 
ischämisches Herzversagen darstellt, suchten wir nach anderen antidiabetischen 
Arzneimitteln, die den Zellmetabolismus der aktivierten Myofibroblasten zugunsten der 
Lipofibroblasten verändern. Infolgedessen, untersuchten wir Metformin im Hinblick auf 
diese Effekte. Die Behandlung von pulmonalen Fibroblasten mit TGFß1 führt zwingend 
zur Transdifferenzierung dieser zu aktivierten Myofibroblasten. Eine anschließende 
Behandlung mit Metformin resultiert in einer effizienten Suppression des TGFß1 
Signalweges und eine Transdifferenzierung der aktivierten Myofibroblasten zu 
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Lipofibroblasten. Um die Situation in humanen Lungen zu simulieren, wurden frisch 
kultivierte Lungenschnitte (precision cut lung slices = PCLS) von Patienten mit 
idiopathische Pulmonalfibrose (IPF) mit Metformin behandelt. Dies führte zu einer 
Verbesserung der pumonalen Mikrostruktur, Reduktion von COL1A1 und Zunahme der 
Lipofibroblasten. Dieselben Ergebnisse erzielten wir, als wir mit Bleomycin behandelte 
Mäuse der Linie ACTA2Cre-ERT2; tdTomatoflox, 14 Tage nach Bleomycin Gabe für 14 
Tage mit Metformin behandelten. Metformin ist ein bekannter Agonist von AMPK. Unsere 
Ergebnisse zeigten, dass Metformin über einen AMPK-abhängigen Mechanismus die 
Expression von COL1A1 reduziert. Andererseits ist die Induktion von lipogenen Marker 
wie PLIN2 und PPARg durch Metformin unabhängig von AMPK. Um den zu Grunde 
liegenden Mechanismus zu verstehen, wurden die Transkriptome der Fibroblasten 72 h 
nach Behandlung mit Metformin untersucht. KEGG Analysen zeigten neben der 
Aktivierung von vielen metabolischen “Pathways” zur Induktion von lipidhaltigen Vesikeln, 
eine deutlich erhöhte Expression von BMP2 im Vergleich zur Kontrollgruppe. Eine 
Behandlung von Fibroblasten mit BMP2 induziert Expression von lipogenen Markern und 
führt zur Akkumulation von lipighaltigen Vesikeln. Jedoch führte BMP2 nicht zur 
reduzierten Expression von COL1A1. Eine posttranslationale Analyse von PPARg nach 
Behandlung mit BMP2 oder Metformin, zeigte einen drastischen Anstieg von Ser-112 in 
PPARg, die zu einer höheren Aktivierung des Proteins führt. Infolgedessen schlußfolgern 
wir, dass Metformin über die Aktivierung von AMPK die Expression von COL1A1 
unterdrückt, während sie parallel die lipogenen Marker über die BMP2-PPARg Achse 
induziert. 
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